Acylsulfonamide compounds, their preparation methods and uses

By developing novel acylsulfonamide compounds that bind to the URAT1 protein, the shortcomings of existing URAT1 inhibitors in terms of safety and efficacy have been addressed, achieving highly efficient and selective treatment of abnormal uric acid levels.

CN118851958BActive Publication Date: 2026-11-10INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202311714555.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2023-04-26
Filing Date
2023-12-14
Publication Date
2026-11-10
Estimated Expiration
2043-12-14

AI Technical Summary

Technical Problem

Existing URAT1 inhibitors have shortcomings in terms of safety and efficacy, making them difficult to effectively treat hyperuricemia and gout.

Method used

A novel class of acylsulfonamide compounds was developed, which, through condensation with URAT1 protein, form compounds with strong URAT1 inhibitory activity, high selectivity, and low cytotoxicity.

Benefits of technology

These compounds exhibit highly efficient URAT1 inhibitory activity, with inhibition rates of 70% or higher, IC50 values ​​below 1 μM, and minimal inhibition of OAT1 with low cytotoxicity, making them suitable for treating conditions related to abnormal uric acid levels.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118851958B_ABST
    Figure CN118851958B_ABST
Patent Text Reader

Abstract

This invention belongs to the field of pharmaceutical technology and discloses acylsulfonamide compounds, their preparation methods, and uses. Specifically, this invention relates to compounds represented by formula (I), their pharmaceutically acceptable salts, and pharmaceutical compositions comprising the compounds of this invention, their methods of use, and methods of preparing these compounds, wherein X, R1, R2, and R3 are as described in the specification. This invention aims to prepare their use in the preparation of urate anion transporter 1 (URAT1) inhibitors, particularly in the preparation of drugs for the prevention and treatment of hyperuricemia or gout.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of pharmaceutical technology. In particular, it relates to acylsulfonamide compounds represented by general formula (I), their preparation methods, pharmaceutical compositions with the compound as the active ingredient, and their use in the treatment and / or prevention of diseases related to abnormal uric acid levels. Background Technology

[0002] Hyperuricemia is a basic metabolic disease caused by excessively high concentrations of uric acid in the blood. Gout develops as uric acid crystals deposit in soft tissues, leading to acute or chronic conditions. Statistics show that approximately 5% to 12% of hyperuricemia cases eventually progress to gout. Hyperuricemia is a crucial biochemical basis for gout. Gout can lead to kidney disease complications; severe cases may experience joint damage, decreased kidney function, and are often accompanied by high blood pressure, high cholesterol, diabetes, coronary heart disease, and arteriosclerosis.

[0003] Hyperuricemia is caused by excessive uric acid production or insufficient renal excretion. Excessive uric acid production is mainly due to dysregulation of enzyme activity during purine metabolism, such as excessive phosphoribosyl pyrophosphate synthase (PRS) activity, decreased hypoxanthine-guanine phosphoribosyltransferase (HPRT) activity, insufficient adenine phosphoribosyltransferase activity, and excessive xanthine oxidase (XO) activity. This leads to increased purine content and increased catabolism in the body, further resulting in the production of large amounts of uric acid. Regarding uric acid excretion, the vast majority of uric acid is filtered by the glomeruli, then resected and reabsorbed by the renal tubules, and finally excreted in the urine. Furthermore, plasma uric acid levels are directly regulated by uric acid transport in the kidneys. Studies suggest that insufficient uric acid excretion accounts for approximately 90% of primary hyperuricemia cases, and inhibiting uric acid reabsorption is crucial for the treatment of gout.

[0004] Recent studies have revealed that various urate transporters are involved in the reabsorption and active secretion of urate in the proximal convoluted tubule of the kidney, including: OATs (organic anion transporters), GLUT9 (glucose transporter 9), URAT1 (urate anion transporter 1), NPT1 (sodium-dependent phosphate transporter 1), and ABCG2 (ATP-binding cassette transporter 2). Among these, URAT1, located at the apical membrane of the proximal tubule of the glomerulus, belongs to the OATs family and is expressed only in the kidney. It reabsorbs urate into the bloodstream through exchange with intracellular anions (such as lactate and niacin). Since approximately 90% of urate is reabsorbed into the bloodstream via URAT1, URAT1 is an important therapeutic target for hyperuricemia.

[0005] Currently available URAT1 inhibitors for lowering uric acid include probenecid, sulfinpyrazone, benzbromarone, and lesinurad. Probenecid, introduced in the 1950s, was discontinued due to serious adverse effects such as suppressing hematopoiesis. Furthermore, it has virtually no uric acid-lowering effect in patients with severely impaired renal function. Sulfinpyrazone, approved by the US Food and Drug Administration (FDA), was withdrawn from the market due to similar serious adverse effects. Benzbromarone, introduced in the 1970s, still exhibits significant uric acid-lowering activity in patients with severely impaired renal function; however, it has been withdrawn from the market in some European countries due to the risk of fulminant hepatitis. Lesinurad received FDA approval in the US in 2015 and EU approval in 2016. However, lesinurad's efficacy is relatively weak and requires combination with xanthine oxidase inhibitors to achieve an effective uric acid-lowering effect. Therefore, further research and development of selective URAT1 inhibitors with excellent efficacy and high safety has important application value.

[0006]

[0007] Patent WO2012033720A1 discloses a class of benzoic acid-based URAT1 inhibitors, among which compounds A-1, A-3, A-4, and A-5 (corresponding to the original patent compounds FA, FD, FB, and FC, respectively) exhibit good URAT1 inhibitory activity. At a concentration of 10 μM, their URAT1 inhibition rates are 83.2%, 68.1%, 81.0%, and 89.2%, respectively. Compound A-5 has an IC50 value of [missing information]. 50 Approximately 1 μM.

[0008] Summary of the Invention

[0009] The technical problem to be solved by this invention is to provide a novel acylsulfonamide compound with strong URAT1 inhibitory activity. This invention discovers that acylsulfonamide compounds have strong URAT1 inhibitory activity, while also exhibiting good selectivity and low cytotoxicity, making them suitable as therapeutic agents for conditions related to abnormal uric acid levels. This invention is based on the above findings. Invention Overview

[0011] Therefore, in a first aspect of the present invention, a compound of formula (I) or a pharmaceutically acceptable salt thereof is provided.

[0012]

[0013] in,

[0014] X is selected from O, S, NH;

[0015] R1 is selected from substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted thiophene, substituted or unsubstituted pyridinyl;

[0016] R2 is selected from H, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylamino, F, Cl, Br, CN, OH, NO2, NH2, trifluoromethyl, and trifluoromethoxy.

[0017] R3 is selected from H, C1-C3 alkyl, C1-C3 alkoxy, F, Cl, and Br;

[0018] The substituent in R1 may be selected from the following groups: hydroxyl, halogen, cyano, amino, nitro, trifluoromethyl, trifluoromethoxy, C 1-3 Alkyl, cycloalkyl, C 1-3 Alkyl group.

[0019] According to any one of the first aspects of the present invention, the compound is a compound of formula (II) or a pharmaceutically acceptable salt thereof.

[0020]

[0021] in,

[0022] R1 is selected from substituted or unsubstituted phenyl, substituted or unsubstituted thiophene, or substituted or unsubstituted pyridinyl.

[0023] R2 is selected from H, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylamino, F, Cl, Br, CN, OH, NO2, NH2, trifluoromethyl, and trifluoromethoxy.

[0024] The substituent in R1 may be selected from the following groups: hydroxyl, halogen, cyano, amino, nitro, trifluoromethyl, trifluoromethoxy, C 1-3 Alkyl, cycloalkyl, C 1-3 Alkyl group.

[0025] According to any one of the first aspects of the present invention, the compound is a compound of formula (III) or a pharmaceutically acceptable salt thereof.

[0026]

[0027] in,

[0028] X is selected from O, S, NH;

[0029] R1 is selected from substituted or unsubstituted C1-C6 alkyl groups and substituted or unsubstituted C3-C6 cycloalkyl groups;

[0030] R2 is selected from H, C1-C3 alkyl, C1-C3 alkoxy, F, Cl, Br, CN, OH, NO2, trifluoromethyl, and trifluoromethoxy.

[0031] R3 is selected from H, C1-C3 alkyl, C1-C3 alkoxy, F, Cl, and Br;

[0032] The substituent in R1 may be selected from the following groups: hydroxyl, halogen, cyano, amino, nitro, trifluoromethyl, trifluoromethoxy, C 1-3 Alkyl, cycloalkyl, C 1-3 Alkyl group.

[0033] According to any one of the first aspects of the present invention, the compound is a compound of formula (IV) or a pharmaceutically acceptable salt thereof.

[0034]

[0035] in,

[0036] R1 is selected from substituted or unsubstituted C1-C6 alkyl groups and substituted or unsubstituted C3-C6 cycloalkyl groups;

[0037] R2 is selected from H, C1-C3 alkyl, C1-C3 alkoxy, F, Cl, Br, CN, OH, NO2, trifluoromethyl, and trifluoromethoxy.

[0038] R3 is selected from H, C1-C3 alkyl groups, F, Cl, and Br;

[0039] The substituent in R1 may be selected from the following groups: hydroxyl, halogen, cyano, amino, nitro, trifluoromethyl, trifluoromethoxy, C 1-3 Alkyl, cycloalkyl, C 1-3 Alkyl group.

[0040] According to any one of the first aspects of the present invention, the compound is a compound of formula (V) or a pharmaceutically acceptable salt thereof.

[0041]

[0042] in,

[0043] R2 is selected from H, C1-C3 alkyl, C1-C3 alkoxy, F, Cl, Br, CN, OH, NO2, trifluoromethyl, and trifluoromethoxy.

[0044] R3 is selected from H, C1-C3 alkyl groups, F, Cl, and Br.

[0045] According to any one of the first aspects of the present invention, the compound is a compound of formula (VI) or a pharmaceutically acceptable salt thereof.

[0046]

[0047] in,

[0048] R2 is selected from H, C1-C3 alkyl, C1-C3 alkoxy, F, Cl, Br, CN, OH, NO2, trifluoromethyl, and trifluoromethoxy.

[0049] R3 is selected from H, C1-C3 alkyl groups, F, Cl, and Br.

[0050] In this invention, C1-C6 alkyl, preferably C1-C4 alkyl, more preferably C1-C3 alkyl; C3-C6 cycloalkyl, preferably C3-C5 cycloalkyl, more preferably C3-C4 cycloalkyl;

[0051] According to any one of the first aspects of the present invention, the target compound of the present invention (represented by a structural formula or described by a systematic name) prepared in the examples or a pharmaceutically acceptable salt thereof.

[0052] According to any one of the first aspects of the present invention, the compound is selected from the following:

[0053]

[0054]

[0055]

[0056]

[0057] A second aspect of the present invention provides a method for preparing the compound according to any one of the first aspects of the present invention, comprising the following steps:

[0058]

[0059] Compound A undergoes a condensation reaction with a substituted sulfonamide compound in a suitable solvent (e.g., DMF, dichloromethane, tetrahydrofuran, acetonitrile, preferably dichloromethane) under the action of a condensation activator (e.g., DCC, DIC, EDC-HCl, HOBt, HATU, HBTU, HCTU, BOP, preferably EDC-HCl) and the catalyst DMAP. The reaction is carried out at 25-80°C for 1-24 hours, preferably at 25°C for 8-10 hours, to obtain the compound shown in formula (I).

[0060] Wherein, X, R1, R2 and R3 are defined as described in the first aspect of the present invention.

[0061] The third aspect of the present invention provides the use of any of the compounds described in the first aspect of the present invention or pharmaceutically acceptable salts thereof in the preparation of urate anion transporter 1 (URAT1) inhibitors.

[0062] A fourth aspect of the present invention provides a pharmaceutical composition comprising a therapeutically and / or preventively effective amount of a compound or a pharmaceutically acceptable salt thereof according to any one of the first aspects of the present invention, and optionally one or more pharmaceutically acceptable excipients.

[0063] The fifth aspect of the present invention provides a pharmaceutical composition as described in the fourth aspect of the present invention, further comprising one or more other uric acid-lowering drugs selected from urate anion transporter 1 (URAT1) inhibitors, xanthine oxidase inhibitors, xanthine dehydrogenase or xanthine oxidoreductase inhibitors, wherein the xanthine oxidase inhibitor is selected from allopurinol, febuxostat or topiptostat.

[0064] The sixth aspect of the present invention provides the use of any of the compounds or pharmaceutically acceptable salts of the compounds described in any of the first aspects of the present invention, or any of the pharmaceutical compositions described in any of the fourth or fifth aspects of the present invention, in the preparation of a medicament for treating hyperuricemia or a medicament for gout.

[0065] The foregoing description only outlines certain aspects of the invention, but is not limited thereto. These and other aspects will be described in more detail below. Invention Details

[0067] The various aspects and features of the present invention will be further described below.

[0068] All references cited in this invention are incorporated herein by reference in their entirety, and in the event of any inconsistency between the meanings expressed in these references and those expressed herein, the meanings expressed herein shall prevail. Furthermore, the various terms and phrases used in this invention have their general meanings known to those skilled in the art; however, this invention still intends to provide a more detailed explanation and interpretation of these terms and phrases. In the event of any inconsistency between the mentioned terms and their known meanings and those expressed herein, the meanings expressed herein shall prevail. The following are definitions of various terms used in this invention, and these definitions apply to all terms used throughout this specification, unless otherwise specified in the specific context.

[0069] Generally, the term "substituted or unsubstituted" indicates that one or more hydrogen atoms in a given structure are substituted by a specific substituent. Unless otherwise indicated, an optional substituent may be substituted at each substituted position of the group. When the given structure is always capable of being substituted at more than one position by one or more substituents selected from a specific group, the substituents may be substituted at each position in the same or different manner.

[0070] C i -C j This indicates a portion having an integer number of carbon atoms from "i" (inclusive) to an integer number of carbon atoms from "i" (inclusive). Therefore, for example, C1-C6 alkyl refers to an alkyl group having 1 to 6 (inclusive) carbon atoms.

[0071] As described herein, the term "alkyl" refers to an alkyl group having a specified number of carbon atoms, which is a straight-chain or branched alkyl group, and may include its daughter groups, for example, when referring to "C1-C6 alkyl", it may also include groups in the subrange of C1-C2 alkyl, as well as specific groups such as methyl, ethyl, n-propyl, isopropyl.

[0072] As described herein, the terms “alkoxy” and “alkylamine” are conventional expressions referring to alkyl groups, which are respectively attached to the remainder of a molecule by an oxygen atom or an amino group, wherein the alkyl group is as described in this invention.

[0073] As described herein, the term "halogenated alkyl" means that the hydrogen atom in an alkyl group is replaced by one or more halogen atoms, and such examples include, but are not limited to, monofluoromethyl, monofluoromethoxy, etc.

[0074] As described herein, the term "cycloalkyl" refers to a cyclic alkyl group having a specified number of cyclic carbon atoms, and may include its subgroups, such as when referring to "C3-C6 cycloalkyl", it may also include subranges such as C3-C5 cycloalkyl, C4-C6 cycloalkyl, etc., as well as specific groups such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0075] As described herein, the term "ring" refers to a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group. So-called rings include fused rings. The number of atoms on a ring is generally defined as the ring element number; for example, a "C3-C6 ring" refers to 3-6 atoms arranged in a ring.

[0076] As described herein, the term "heteroatom" refers to O, S, N, including any oxidation state of N and S; primary, secondary, tertiary amines and quaternary ammonium salts; or forms in which hydrogen atoms on nitrogen atoms in heterocycles are substituted.

[0077] As described in this article, the terms “halogen”, “halogenated”, etc., refer to fluorine (F), chlorine (Cl), or bromine (Br).

[0078] In this invention, "room temperature" refers to a temperature ranging from 10°C to 40°C. In some embodiments, "room temperature" refers to a temperature ranging from 20°C to 30°C; in other embodiments, room temperature refers to 25°C.

[0079] As described herein, the term "effective amount" refers to a dosage of medicine that can achieve the desired therapeutic effect on the disease or condition described in this invention in a subject.

[0080] As described herein, the term "pharmaceutically acceptable," for example, when describing "pharmaceutically acceptable salt," indicates that the salt is not only physiologically acceptable to the subject but can also refer to a synthetic substance that has pharmaceutical value.

[0081] As described herein, the term "pharmaceutical composition" can also refer to a "composition" which can be used to treat the disease or condition described in this invention in subjects, particularly mammals.

[0082] The “treatment” of the disease includes:

[0083] (1) Prevention of the disease, that is, preventing the development of clinical symptoms of the disease in mammals that are exposed to or susceptible to the disease but do not experience or show symptoms of the disease.

[0084] (2) Inhibit the disease, that is, stop or reduce the progression of the disease or its clinical symptoms.

[0085] (3) To alleviate the disease, that is, to restore the disease or its clinical symptoms.

[0086] "Therapeutic effective amount" refers to the amount of a compound sufficient to treat a disease when administered to a mammal. Therapeutic effective amount will vary depending on the compound, the disease to be treated and its severity, and factors such as the mammal's age, weight, and sex. Therapeutic effective amount can also refer to any amount of a compound sufficient to achieve the desired beneficial effect, including disease prevention, disease inhibition, or disease ablation as described in (1)-(3) above. For example, the amount of the compound may be between 0.1-250 mg / kg, or preferably, 0.5-100 mg / kg, or more preferably, 1-50 mg / kg, or even more preferably, 2-20 mg / kg. Preferably, the amount of the compound is administered to the mammal twice daily. More preferably, the amount of the compound is administered to the mammal once daily.

[0087] As described herein, the term "disease and / or symptom" refers to a physical condition of the subject that is related to the disease and / or symptom described in this invention. For example, the disease and / or symptom described in this invention refers to a symptom associated with abnormal uric acid levels.

[0088] As described herein, the term "subject" may refer to a patient or other animal, particularly a mammal, such as a human, dog, monkey, cow, horse, etc., that receives a compound of Formula I of the present invention or a pharmaceutical composition thereof to treat the disease or condition described herein.

[0089] Another aspect of the invention relates to pharmaceutical compositions using compounds of the invention as active ingredients. These pharmaceutical compositions can be prepared according to methods known in the art. They can be formulated into any dosage form suitable for human or animal use by combining the compounds of the invention with one or more pharmaceutically acceptable solid or liquid excipients and / or adjuvants.

[0090] The compounds or pharmaceutical compositions containing them in this invention can be administered in unit dose form via enteral or non-enteric routes, such as oral, intravenous, intramuscular, subcutaneous, nasal, oral mucosa, eye, lung and respiratory tract, skin, vagina, rectum, etc.

[0091] Dosage forms can be liquid, solid, or semi-solid. Liquid dosage forms can include solutions (including true solutions and colloidal solutions), emulsions (including o / w, w / o, and double emulsions), suspensions, injections (including aqueous injections, powder injections, and infusions), eye drops, nasal drops, lotions, and liniments, etc.; solid dosage forms can include tablets (including regular tablets, enteric-coated tablets, lozenges, dispersible tablets, chewable tablets, effervescent tablets, and orally disintegrating tablets), capsules (including hard capsules, soft capsules, and enteric-coated capsules), granules, powders, microcapsules, pellets, suppositories, films, patches, aerosols, and sprays, etc.; semi-solid dosage forms can include ointments, gels, and pastes, etc.

[0092] The compounds of this invention can be formulated into conventional formulations, sustained-release formulations, controlled-release formulations, targeted formulations, and various microparticle delivery systems.

[0093] To formulate the compounds of the present invention into tablets, a wide variety of excipients known in the art can be used, including diluents, binders, wetting agents, disintegrants, lubricants, and solubilizers. Diluents can be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, dicalcium phosphate, calcium carbonate, etc.; wetting agents can be water, ethanol, isopropanol, etc.; binders can be starch paste, dextrin, syrup, honey, glucose solution, microcrystalline cellulose, gum arabic paste, gelatin paste, sodium carboxymethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, ethyl cellulose, acrylic resin, carbomer, polyvinylpyrrolidone, polyethylene glycol, etc.; disintegrants can be dry starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, croscarmellose, croscarmellose sodium carboxymethyl cellulose, sodium carboxymethyl starch, sodium bicarbonate and citric acid, polyoxyethylene sorbitol fatty acid ester, sodium dodecyl sulfonate, etc.; lubricants and cosolvents can be talc, silica, stearate, tartaric acid, liquid paraffin, polyethylene glycol, etc.

[0094] Tablets can also be further processed into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or bilayer and multilayer tablets.

[0095] To formulate the drug delivery unit into capsules, the active ingredient, the compound of the present invention, can be mixed with a diluent and a solubilizer, and the mixture can be placed directly into hard or soft capsules. Alternatively, the active ingredient, the compound of the present invention, can be first formed into granules or microspheres with a diluent, binder, and disintegrant, and then placed into hard or soft capsules. The diluents, binders, wetting agents, disintegrants, and solubilizers used to prepare tablets of the compound of the present invention can also be used to prepare capsules of the compound of the present invention.

[0096] To prepare the compounds of this invention into injectable formulations, water, ethanol, isopropanol, propylene glycol, or mixtures thereof can be used as solvents, and appropriate amounts of commonly used solubilizers, co-solvents, pH adjusters, and osmotic pressure adjusters can be added. Solubilizers or co-solvents can be poloxamer, lecithin, hydroxypropyl-β-cyclodextrin, etc.; pH adjusters can be phosphates, acetates, hydrochloric acid, sodium hydroxide, etc.; osmotic pressure adjusters can be sodium chloride, mannitol, glucose, phosphates, acetates, etc. If preparing lyophilized powder injections, mannitol, glucose, etc., can also be added as supporting agents.

[0097] In addition, colorants, preservatives, flavorings, tasters or other additives may be added to pharmaceutical preparations if necessary.

[0098] To achieve the purpose of medication and enhance the therapeutic effect, the drug or drug composition of the present invention can be administered using any known method of administration.

[0099] The compounds or compositions of the present invention can be taken alone or in combination with other therapeutic or symptomatic drugs. When the compounds of the present invention have a synergistic effect with other therapeutic drugs, their dosage should be adjusted according to the actual situation.

[0100] Beneficial technical effects

[0101] The compounds in this invention generally exhibit strong URAT1 inhibitory activity. The inhibition rate (IR) of 33 compounds reached 70% or higher, demonstrating superior activity compared to the positive control drug ricinard. The IC50 of 28 compounds showed strong URAT1 inhibitory activity. 50 <1 μM, with IC50 values ​​of compounds 14, 35, 39 and 40. 50 Compounds 14, 35, and 39 showed extremely strong in vitro URAT1 inhibitory activity at concentrations of 0.042 μM, 0.088 μM, 0.078 μM, and 0.063 μM, respectively. Furthermore, compounds 14, 35, and 39 exhibited minimal inhibitory activity against OAT1 (organic anion transporter 1), indicating the superior selectivity of the compounds of this invention. In addition, these compounds showed low Vero cytotoxicity (IC50). 50 The concentration (greater than 64 μg / mL) indicates that this class of compounds has good safety. This invention provides a new class of compounds with novel structures, strong in vitro URAT1 inhibitory activity, and low cytotoxicity, which can be used in drugs that inhibit URAT1, and particularly as therapeutic agents for conditions related to abnormal uric acid levels. Detailed Implementation

[0102] The present invention will be described in detail through the following embodiments, but this does not imply any adverse limitation on the invention. The present invention has been described in detail herein, and specific embodiments thereof have also been disclosed. It will be apparent to those skilled in the art that various changes and modifications can be made to the specific embodiments of the present invention without departing from the spirit and scope thereof.

[0103] For all the following examples, standard operating and purification methods known to those skilled in the art were used. Unless otherwise stated, all temperatures are expressed in °C (degrees Celsius). The structures of the compounds were determined by nuclear magnetic resonance (NMR) spectroscopy and / or mass spectrometry (MS).

[0104] Preparation Examples

[0105] The structure of the compound was determined by 1H NMR spectroscopy (NMR spectroscopy). 1The NMR spectra were determined by 1H NMR. The shifts (δ) of the 1H and 1C NMR spectra are given in parts per million (ppm). The coupling constant (J) is expressed in Hertz (Hz). NMR spectra were determined using a Mercury-400 or Brucker-500 NMR spectrometer, with deuterated chloroform (CDCl3) or deuterated dimethyl sulfoxide (DMSO-d6) as solvent and tetramethylsilane (TMS) as an internal standard.

[0106] High-resolution mass spectrometry was performed using an Agilent 1100 series LC / MSD trap mass spectrometer.

[0107] The electronic balance used is the Japanese Yanaco LY-300 model.

[0108] Column chromatography typically uses 200-300 mesh silica gel as a carrier.

[0109] All anhydrous solvents were processed using standard methods. All other reagents were commercially available analytical grade.

[0110] This invention uses the following abbreviations:

[0111] DCM stands for dichloromethane.

[0112] MeOH is methanol.

[0113] THF stands for tetrahydrofuran.

[0114] K2CO3 is potassium carbonate.

[0115] NaOH is sodium hydroxide.

[0116] HCl is hydrochloric acid.

[0117] DMF is N,N-dimethylformamide.

[0118] DMSO stands for dimethyl sulfoxide.

[0119] CDCl3 is deuterated chloroform.

[0120] DMSO-d6 is deuterated dimethyl sulfoxide.

[0121] EA stands for ethyl acetate.

[0122] Et3N(TEA / NEt3) is triethylamine.

[0123] PE is petroleum ether.

[0124] DIAD stands for diisopropyl azodicarbonate.

[0125] PPh3 is triphenylphosphine.

[0126] EDC-HCl is 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride.

[0127] DMAP is 4-dimethylaminopyridine.

[0128] HOBt is 1-hydroxybenzotriazole.

[0129] HATU is 2-(7-benzotriazole oxide)-N,N,N',N'-tetramethylurea hexafluorophosphate.

[0130] DME stands for ethylene glycol dimethyl ether.

[0131] DABCO stands for triethylenediamine.

[0132] Preparation Example

[0133] Preparation Example 1

[0134] Preparation of 3-((2,6-dimethylbenzyl)oxy)-4-methylbenzoic acid (A-1)

[0135]

[0136] Step 1: Preparation of 1a

[0137] Ethyl 3-hydroxy-4-methylbenzoate (5.4 g, 30 mmol), (2,6-dimethylphenyl)methanol (5.7 g, 42 mmol), and PPh3 (12 g, 45 mmol) were added to a 50 mL three-necked flask, and anhydrous THF (10 mL) was added as a solvent. Under Ar atmosphere protection, DIAD (8.9 mL, 45 mmol) was slowly added to the reaction system in an ice bath. After the addition was complete, the reaction was allowed to proceed to room temperature. After 5 hours of reaction, TLC confirmed the reaction was complete. The reaction solution was evaporated to dryness, diluted with water (15 mL), and extracted three times with ethyl acetate (15 mL). The organic phases were combined and washed three times with saturated NaCl aqueous solution. After drying the organic phase with anhydrous sodium sulfate, silica gel column chromatography (EA / PE = 5 / 95) was performed to give intermediate 1a, 8.28 g of white solid, yield 93%.

[0138] 1 H NMR (400MHz, CDCl3) δ7.67(d,J=1.6Hz,1H),7.58(dd,J=7.6,1.6Hz,1H),7.20–7.14(m,2H),7.07(d ,J=7.6Hz,2H),5.09(s,2H),4.38(q,J=7.2Hz,2H),2.39(s,6H),2.19(s,3H),1.40(t,J=7.0Hz,3H).

[0139] Step 2: Preparation of A-1

[0140] Intermediate 1a (1 g, 3.4 mmol) was added to a 25 mL round-bottom flask, and methanol (10 mL) was added as a solvent. NaOH (268 mg, 6.7 mmol) was added, and the reaction was carried out at 80 °C for 3 hours. The reaction was confirmed to be complete by TLC. The reaction solution was concentrated under reduced pressure to remove most of the organic solvent, and then diluted with water (15 mL). The pH of the reaction solution was slowly adjusted to 2-3 with 2N hydrochloric acid aqueous solution, causing a solid to precipitate. The solid was filtered, dried, and A-1 was obtained, a white solid of 845 mg, with a yield of 92%.

[0141] 1 H NMR (400MHz, CDCl3) δ7.73(s,1H),7.68(d,J=7.6Hz,1H),7.24–7.15(m,2H),7.08(d,J=7.6Hz,2H),5.11(s,2H),2.40(s,6H),2.22(s,3H).

[0142] Preparation Example 2

[0143] Preparation of 3-((2,6-dimethylbenzyl)oxy)benzoic acid (A-2)

[0144]

[0145] Step 1: Preparation of 2a

[0146] Using methyl 3-hydroxybenzoate (1 g, 6.57 mmol) as a raw material, and following a similar procedure to the first step in Preparation Example 1, intermediate 2a was obtained, consisting of 1.708 g of a white solid, with a yield of 96%.

[0147] 1 H NMR (400MHz, CDCl3) δ7.70–7.65(m,2H),7.36(t,J=8.0Hz,1H),7.20–7.14(m,2H),7.09(s,1H),7.07(s,1H),5.08(s,2H),3.92(s,3H),2.39(s,6H).

[0148] Step 2: Preparation of A-2

[0149] Using intermediate 2a (500 mg, 1.85 mmol) as a starting material, and following a similar procedure to the second step in Preparation Example 1, A-2 was obtained, a white solid of 457 mg, with a yield of 96%.

[0150] 1H NMR (400MHz, DMSO-d6) δ13.04(s,1H),7.60–7.58(m,2H),7.46(t,J=8.0Hz,1H),7.31(d ,J=8.4Hz,1H),7.21–7.17(m,1H),7.11(s,1H),7.09(s,1H),5.12(s,2H),2.36(s,6H).

[0151] Preparation Example 3

[0152] Preparation of 3-((2,6-dimethylbenzyl)oxy)-4-fluorobenzoic acid (A-3)

[0153]

[0154] Step 1: Preparation of 3a

[0155] Using methyl 4-fluoro-3-hydroxybenzoate (1 g, 5.88 mmol) as a raw material, and following a similar procedure to the first step in Preparation Example 1, intermediate 3a was obtained, consisting of 1.616 g of a white solid, with a yield of 95%.

[0156] 1 H NMR (400MHz, CDCl3) δ7.82(dd,J=8.0,2.0Hz,1H),7.68–7.64(m,1H),7.18–7.11(m,2H),7.09–7.06(m,2H),5.14(s,2H),3.92(s,3H),2.41(s,6H).

[0157] Step 2: Preparation of A-3

[0158] Using intermediate 3a (500 mg, 1.734 mmol) as the starting material, and following a similar procedure to the second step in Preparation Example 1, A-3 was obtained, a white solid of 410 mg, with a yield of 86%.

[0159] 1 H NMR(400MHz, DMSO-d6)δ13.14(s,1H),7.90(dd,J=8.2,2.2Hz,1H),7.64–7.61(m,1H), 7.39–7.34(m,1H),7.20(t,J=7.6Hz,1H),7.11–7.10(m,2H),5.22(s,2H),2.37(s,6H).

[0160] Preparation Example 4

[0161] Preparation of 3-((2,6-dimethylbenzyl)oxy)-4-nitrobenzoic acid (A-4)

[0162]

[0163] Step 1: Preparation of 4a

[0164] Using methyl 4-nitro-3-hydroxybenzoate (1 g, 5.07 mmol) as a starting material, and following a similar procedure to the first step in Preparation Example 1, intermediate 4a was obtained, consisting of 1.152 g of a yellow solid, with a yield of 72%.

[0165] 1 H NMR (400MHz, CDCl3) δ7.92 (d, J=1.2Hz, 1H), 7.70 (dd, J=8.2, 1.4Hz, 1H), 7.19–7. 15(m,1H),7.07(s,1H),7.00–6.99(m,2H),5.23(s,2H),3.97(s,3H),2.40(s,6H).

[0166] Step 2: Preparation of A-4

[0167] Using intermediate 4a (500 mg, 1.586 mmol) as a starting material, and following a similar procedure to the second step in Preparation Example 1, A-4 was obtained, a white solid of 470 mg, with a yield of 99%.

[0168] 1 H NMR (500MHz, DMSO-d6) δ13.44(s,1H),7.85(s,1H),7.78(d,J=8.0Hz,1H),7.50( d,J=8.5Hz,1H),7.02–6.99(m,1H),6.91–6.90(m,2H),5.15(s,2H),2.17(s,6H).

[0169] Preparation Example 5

[0170] Preparation of 3-((2,6-dimethylbenzyl)oxy)-4-methoxybenzoic acid (A-5)

[0171]

[0172] Step 1: Preparation of 5a

[0173] Using methyl 4-methoxy-3-hydroxybenzoate (1 g, 5.49 mmol) as a starting material, and following a similar procedure to the first step in Preparation Example 1, intermediate 5a was obtained, consisting of 1.488 g of a white solid, with a yield of 90%.

[0174] 1H NMR(400MHz, CDCl3)δ7.71–7.69(m,2H),7.13(dd,J=8.4,6.8Hz,1H),7.05–7.03( m,2H),6.89(d,J=8.8Hz,1H),5.10(s,2H),3.90(s,3H),3.86(s,3H),2.40(s,6H).

[0175] Step 2: Preparation of A-5

[0176] Using intermediate 5a (500 mg, 1.66 mmol) as a starting material, and following a similar procedure to the second step in Preparation Example 1, A-5 was obtained, a white solid of 470 mg, with a yield of 99%.

[0177] 1 H NMR(400MHz,DMSO-d6)δ7.60(d,J=2.0Hz,1H),7.56(dd,J=8.4,2.0Hz,1H),7 .14–7.10(m,1H),7.03–7.01(m,3H),5.02(s,2H),3.75(s,3H),2.28(s,6H).

[0178] Preparation Example 6

[0179] Preparation of 3-((2,6-dimethylbenzyl)oxy)-4-cyanobenzoic acid (A-6)

[0180]

[0181] Step 1: Preparation of 6a

[0182] Using methyl 4-cyano-3-hydroxybenzoate (250 mg, 1.41 mmol) as the starting material, and following a similar procedure to the first step in Preparation Example 1, intermediate 6a was obtained, consisting of 400 mg of a white solid, with a yield of 96%.

[0183] 1 H NMR (400MHz, CDCl3) δ7.82(s,1H),7.71–7.64(m,2H),7.21–7.17(m,1H),7.09–7.07(m,2H),5.24(s,2H),3.98(s,3H),2.43(s,6H).

[0184] Step 2: Preparation of A-6

[0185] Using intermediate 6a (400 mg, 1.35 mmol) as a starting material, and following a similar procedure to the second step in Preparation Example 1, A-6 was obtained, consisting of 288 mg of an off-white solid, with a yield of 76%.

[0186] 1 H NMR(400MHz,DMSO-d6)δ7.93(s,1H),7.87(d,J=8.0Hz,1H),7.66(d,J=8.0Hz,1H), 7.24–7.20(m,1H),7.13–7.12(m,1H),7.01–7.00(m,1H),5.33(s,2H),2.40(s,6H).

[0187] Preparation Example 7

[0188] Preparation of 3-((2,6-dimethylbenzyl)oxy)-4-trifluoromethylbenzoic acid (A-7)

[0189]

[0190] Step 1: Preparation of 7a

[0191] Using methyl 4-trifluoromethyl-3-hydroxybenzoate (100 mg, 0.45 mmol) as the starting material, and following a similar procedure to the first step in Preparation Example 1, intermediate 7a was obtained, consisting of 89 mg of a yellow oil, with a yield of 76%.

[0192] 1 H NMR (400MHz, CDCl3) δ7.85(s,1H),7.72–7.64(m,2H),7.20–7.17(m,1H),7.09–7.07(m,2H),5.18(s,2H),3.98(s,3H),2.40(s,6H).

[0193] Step 2: Preparation of A-7

[0194] Using intermediate 7a (330 mg, 0.98 mmol) as a starting material, and following a similar procedure to the second step in Preparation Example 1, A-7 was obtained, a white solid of 86 mg, with a yield of 95%.

[0195] 1 H NMR (400MHz, DMSO-d6) δ7.89 (s, 1H), 7.72 (d, J = 8.0Hz, 1H), 7.63 (d, J = 8.0Hz, 1H),7.13(dd,J=8.4,6.8Hz,1H),7.05–7.03(m,2H),5.21(s,2H),2.29(s,6H).

[0196] Preparation Example 8

[0197] Preparation of 3-((2,6-dimethylbenzyl)oxy)-2-methylbenzoic acid (A-8)

[0198]

[0199] Step 1: Preparation of 8a

[0200] Using methyl 2-methyl-3-hydroxybenzoate (1 g, 6.02 mmol) as a starting material, and following a similar procedure to the first step in Preparation Example 1, intermediate 8a was obtained, yielding 1.70 g of a yellow solid with a yield of 99%.

[0201] 1 H NMR (500MHz, CDCl3) δ7.43(d,J=7.5Hz,1H),7.25–7.22(m,2H),7.16(s,1H),7.09–7.07(m,2H),5.04(s,2H),3.88(s,3H),2.39(s,6H),2.37(s,3H).

[0202] Step 2: Preparation of A-8

[0203] Using intermediate 8a (500 mg, 1.76 mmol) as a starting material, and following a similar procedure to the second step in Preparation Example 1, A-8 was obtained, a white solid of 429 mg, with a yield of 90%.

[0204] 1 H NMR (400MHz, DMSO-d6) δ7.40–7.30(m,3H),7.26(dd,J=8.2,6.6Hz,1H),7.18–7.16(m,2H),5.14(s,2H),2.43(s,6H),2.30(s,3H).

[0205] Preparation Example 9

[0206] Preparation of 5-((2,6-dimethylbenzyl)oxy)-2-methylbenzoic acid (A-9)

[0207]

[0208] Step 1: Preparation of 9a

[0209] Using methyl 2-methyl-5-hydroxybenzoate (1 g, 6.02 mmol) as a starting material, and following a similar procedure to the first step in Preparation Example 1, intermediate 9a was obtained, consisting of 1.28 g of a white solid, with a yield of 75%.

[0210] 1H NMR(400MHz,DMSO-d6)δ7.39(d,J=2.8Hz,1H),7.23–7.21(m,1H),7.13(d,J=2.8Hz,1H),7.12 –7.09(m,1H),7.03(s,1H),7.01(s,1H),5.01(s,2H),3.78(s,3H),2.39(s,3H),2.27(s,6H).

[0211] Step 2: Preparation of A-9

[0212] Using intermediate 9a (500 mg, 1.76 mmol) as the starting material, and following a similar procedure to the second step in Preparation Example 1, A-9 was obtained, a white solid of 467 mg, with a yield of 98%.

[0213] 1 ¹H NMR (400 MHz, DMSO-d⁶) δ 7.40 (d, J = 2.8 Hz, 1H), 7.19–7.17 (m, 1H), 7.13–7.07 (m, 2H), 7.03 (s, 1H), 7.01 (s, 1H), 5.00 (s, 2H), 2.40 (s, 3H), 2.27 (s, 6H). Preparation Example 10

[0214]

[0215] 3-((2,6-dimethylbenzyl)thio)-4-methylbenzoic acid (A-10)

[0216] Synthesis route:

[0217]

[0218] Step 1: Preparation of 10a

[0219] (2,6-Dimethylphenyl)methanethiol (280 mg, 1.84 mmol) was added to a 50 mL round-bottom flask. DME (10 mL) was added as a solvent, followed by DABCO (41 μL, 0.37 mmol), CuI (35 mg, 0.18 mmol), K2CO3 (636 mg, 4.6 mmol), and methyl 3-iodo-4-methylbenzoate (762 mg, 2.76 mmol). The reaction was initiated at 90 °C under Ar protection. After 7 hours, the reaction was confirmed to be complete by TLC. Water (5 mL) was added to quench the reaction, and the mixture was extracted three times with DCM (3 × 10 mL). The organic phases were combined and washed three times with saturated NaCl aqueous solution. The organic phase was dried over anhydrous sodium sulfate, and the filtrate was concentrated and subjected to silica gel column chromatography (DCM / PE = 25 / 75) to give intermediate 10a, 183 mg of brown solid, with a yield of 33%.

[0220] 1 H NMR (400MHz, CDCl3) δ8.04(s,1H),7.81(dd,J=7.8,1.8Hz,1H),7.29(d,J=4.8Hz,1H),7.14(dd,J =8.6,6.2Hz,1H),7.09(s,1H),7.07(s,1H),4.23(s,2H),3.97(s,3H),2.45(s,6H),2.40(s,3H).

[0221] Step 2: Preparation of A-10

[0222] Using intermediate 10a (170 mg, 0.57 mmol) as the starting material, and following a similar procedure to the second step in Preparation Example 1, A-10 was obtained, consisting of 125 mg of an off-white solid, with a yield of 77%.

[0223] 1 H NMR (400MHz, DMSO-d6) δ12.98(s,1H),7.96(d,J=1.6Hz,1H),7.74(dd,J=7.6,1.6Hz,1H),7.38 (d,J=8.0Hz,1H),7.14–7.10(m,1H),7.07–7.05(m,2H),4.22(s,2H),2.37(s,6H),2.34(s,3H).

[0224] Preparation Example 11

[0225]

[0226] 3-((2,6-dimethylbenzyl)amino)-4-methylbenzoic acid (A-11)

[0227] Synthesis route:

[0228]

[0229] Step 1: Preparation of 11a

[0230] Methyl 3-amino-4-methylbenzoate (300 mg, 1.82 mmol) was added to a 25 mL round-bottom flask. Anhydrous DCM (8 mL) was added as solvent, followed by 2,6-dimethylbenzaldehyde (366 mg, 2.72 mmol). After reacting for 30 mins, sodium triacetoxyborohydride (1.16 g, 5.46 mmol) was added. The reaction was initiated at room temperature. After 6 hours, the reaction was confirmed to be complete by TLC. Water (5 mL) was added to quench the reaction, and the mixture was extracted three times with DCM (3 × 10 mL). The organic phases were combined and washed three times with saturated NaCl aqueous solution. The organic phase was dried over anhydrous sodium sulfate, and the filtrate was concentrated and subjected to silica gel column chromatography (EA / PE = 5 / 95) to give intermediate 11a, a white solid of 322 mg, with a yield of 63%.

[0231] 1 H NMR (400MHz, CDCl3) δ7.45(s,1H),7.41(d,J=8.0Hz,1H),7.18–7.13(m,2H),7.11–7.08(m,2H),4.33(s,2H),3.92(s,3H),2.38(s,6H),2.10(s,3H).

[0232] Step 2: Preparation of A-11

[0233] Using intermediate 11a (160 mg, 0.56 mmol) as a starting material, and following a similar procedure to the second step in Preparation Example 1, A-11 was obtained, a white solid of 108 mg, with a yield of 72%.

[0234] 1 H NMR(400MHz,DMSO-d6)δ12.59(s,1H),7.27(s,1H),7.21(d,J=7.6Hz,1H),7 .15–7.10(m,2H),7.08–7.06(m,2H),4.22(s,2H),2.37(s,6H),2.13(s,3H). Preparation Example 12

[0235]

[0236] 4-Methyl-3-((2,4,6-trimethylbenzyl)oxy)benzoic acid (A-12)

[0237] Synthesis route:

[0238]

[0239] Step 1: Preparation of 12a

[0240] Using methyl 3-hydroxy-4-methylbenzoate (800 mg, 4.81 mmol) and 2,4,6-trimethylmethanol (1.01 g, 6.74 mmol) as raw materials, and following a similar procedure to the first step in Preparation Example 1, intermediate 12a was obtained, consisting of 1.38 g of a yellow oily substance, with a yield of 96%.

[0241] 1 H NMR (400MHz, CDCl3) δ7.67 (d, J=1.6Hz, 1H), 7.58 (dd, J=7.6, 1.6Hz, 1H), 7.19 (d, J=7.6 Hz,1H),6.91(s,2H),5.06(s,2H),3.93(s,3H),2.36(s,6H),2.30(s,3H),2.20(s,3H).

[0242] Step 2: Preparation of A-12

[0243] Using intermediate 12a (800 mg, 2.68 mmol) as a starting material, and following a similar procedure to the second step in Preparation Example 1, A-12 was obtained, a yellow solid of 700 mg, with a yield of 92%.

[0244] 1 H NMR (400MHz, DMSO-d6) δ7.66(s,1H),7.48(d,J=7.6Hz,1H),7.22(d,J=7.6Hz,1H),6.91(s,2H),5.06(s,2H),2.32(s,6H),2.26(s,3H),2.12(s,3H).

[0245] Preparation Example 13

[0246]

[0247] 4-Methyl-3-((4-fluoro-2,6-dimethylbenzyl)oxy)benzoic acid (A-13)

[0248] Synthesis route:

[0249]

[0250] Step 1: Preparation of 13a

[0251] Using methyl 3-hydroxy-4-methylbenzoate (660 mg, 3.97 mmol) and (4-fluoro-2,6-dimethylphenyl)methanol (612 mg, 3.97 mmol) as raw materials, and following a similar procedure to the first step in Preparation Example 1, intermediate 13a was obtained, consisting of 657 mg of a powdery white solid, with a yield of 67%.

[0252] 1 H NMR (400MHz, CDCl3) δ7.66 (d, J=1.6Hz, 1H), 7.60 (dd, J=7.6, 1.6Hz, 1H), 7.21 (dd, J=7 .8,1.4Hz,1H),6.81–6.78(m,2H),5.04(s,2H),3.93(s,3H),2.39(s,6H),2.20(s,3H).

[0253] Step 2: Preparation of A-13

[0254] Using intermediate 13a (650 mg, 2.15 mmol) as a starting material, and following a similar procedure to the second step in Preparation Example 1, A-13 was obtained, a white solid of 570 mg, with a yield of 92%.

[0255] 1 H NMR (400MHz, DMSO-d6) δ7.66 (d, J=1.6Hz, 1H), 7.49 (dd, J=7.8, 1.4Hz, 1H), 7. 25(d,J=7.6Hz,1H),6.96–6.94(m,2H),5.07(s,2H),2.36(s,6H),2.12(s,3H).

[0256] Preparation Example 14

[0257]

[0258] 3-((2,6-dimethylbenzyl)thio)-4-methoxybenzoic acid (A-14)

[0259] Synthesis route:

[0260]

[0261] Step 1: Preparation of 14a

[0262] Using methyl 3-iodo-4-methoxybenzoate (1.295 g, 4.43 mmol) and (2,6-dimethylphenyl)methanethiol (450 mg, 2.96 mmol) as raw materials, and following a similar procedure to the first step in Preparation Example 10, intermediate 14a was obtained, consisting of 251 mg of brown solid, with a yield of 27%.

[0263] 1H NMR(400MHz, CDCl3)δ8.01(d,J=2.4Hz,1H),7.93–7.91(m,1H),7.10–7.05(m,1H),7.03– 7.01(m,2H),6.88(d,J=8.4Hz,1H),4.16(s,2H),3.94(s,3H),3.91(s,3H),2.43(s,6H).

[0264] Step 2: Preparation of A-14

[0265] Using intermediate 14a (225 mg, 0.71 mmol) as a starting material, and following a similar procedure to the second step in Preparation Example 10, A-14 was obtained, consisting of 211 mg of an off-white solid, with a yield of 99%.

[0266] 1 H NMR(400MHz,DMSO-d6)δ7.84(d,J=2.0Hz,1H),7.80(dd,J=8.6,2.2Hz,1H),7.09–7.05(m,1H), 7.05–7.02(m,1H),7.00(s,1H),6.98(d,J=2.4Hz,1H),4.10(s,2H),3.85(s,3H),2.32(s,6H).

[0267] Preparation Example 15

[0268]

[0269] 3-((2,6-dimethylbenzyl)thio)benzoic acid (A-15)

[0270] Synthesis route:

[0271]

[0272] Step 1: Preparation of 15a

[0273] Using methyl 3-iodobenzoate (1.472 g, 5.62 mmol) and (2,6-dimethylphenyl)methanethiol (570 mg, 3.74 mmol) as raw materials, and following a similar procedure to the first step in Preparation Example 10, intermediate 15a was obtained, consisting of 382 mg of a reddish-brown solid, with a yield of 36%.

[0274] 1H NMR(400MHz, CDCl3)δ8.03(t,J=1.8Hz,1H),7.89–7.86(m,1H),7.53–7.50(m,1H),7.36(t,J=7.8Hz ,1H),7.11–7.07(m,1H),7.03(s,1H),7.02(d,J=1.6Hz,1H),4.21(s,2H),3.93(s,3H),2.39(s,6H).

[0275] Step 2: Preparation of A-15

[0276] Using intermediate 15a (150 mg, 0.55 mmol) as a starting material, and following a similar procedure to the second step in Preparation Example 10, A-15 was obtained, a white solid of 81 mg, with a yield of 39%.

[0277] 1 H NMR(400MHz, DMSO-d6)δ7.90(t,J=1.8Hz,1H),7.78–7.75(m,1H),7.54–7..52(m,1H),7.40(t, J=7.6Hz,1H),7.10–7.06(m,1H),7.04(s,1H),7.02(d,J=2.0Hz,1H),4.24(s,2H),2.35(s,6H).

[0278] Preparation Example 16

[0279]

[0280] 3-((4-fluoro-2,6-dimethylbenzyl)amino)-4-methylbenzoic acid (A-16)

[0281] Synthesis route:

[0282]

[0283] Step 1: Preparation of 16a

[0284] Using methyl 3-amino-4-methylbenzoate (300 mg, 1.82 mmol) and 4-fluoro-2,6-dimethylbenzaldehyde (250 mg, 1.64 mmol) as raw materials, and following a similar procedure to the first step in Preparation Example 11, 16a was obtained, a white solid of 113 mg, with a yield of 23%.

[0285] 1H NMR (400MHz, CDCl3) δ7.52(s,1H),7.15(d,J=7.6Hz,1H),6.77(d,J=9.2Hz,2H),4.31(s,2H),3.92(s,3H),2.33(s,6H),2.14(s,3H).

[0286] Step 2: Preparation of A-16

[0287] Using intermediate 16a (160 mg, 0.56 mmol) as a starting material, and following a similar procedure to the second step in Preparation Example 1, A-16 was obtained, a white solid of 108 mg, with a yield of 72%.

[0288] 1 H NMR(400MHz, DMSO-d6)δ7.25(d,J=1.6Hz,1H),7.21–7.19(m,1H),7.09(d,J= 7.6Hz,1H),6.92(s,1H),6.90(s,1H),4.17(s,2H),2.36(s,6H),2.11(s,3H).

[0289] Preparation Example 17

[0290]

[0291] 3-((2,6-dimethylbenzyl)amino)-4-methoxybenzoic acid (A-17)

[0292] Synthesis route:

[0293]

[0294] Step 1: Preparation of 17a

[0295] Using methyl 3-amino-4-methoxybenzoate (1.0 g, 5.52 mmol) and 2,6-dimethylbenzaldehyde (1.111 g, 8.28 mmol) as raw materials, and following a similar procedure to the first step in Preparation Example 11, 17a was obtained, a white solid of 113 mg, with a yield of 23%.

[0296] 1 H NMR(400MHz, CDCl3)δ7.49–7.46(m,1H),7.41(d,J=2.0Hz,1H),7.17–7.12(m,1H),7.0 9–7.07(m,2H),6.78–6.75(m,1H),4.29(s,2H),3.91(s,3H),3.83(s,3H),2.38(s,6H).

[0297] Step 2: Preparation of A-17

[0298] Using intermediate 17a (1.25 g, 4.18 mmol) as the starting material, and following a similar procedure to the second step in Preparation Example 1, A-17 was obtained, a white solid of 1.152 g, with a yield of 97%.

[0299] 1 H NMR(500MHz,DMSO-d6)δ7.32–7.30(m,1H),7.26(d,J=2.0Hz,1H),7.14–7.11(m,1H),7 .07(s,1H),7.05(s,1H),6.89(d,J=8.5Hz,1H),4.20(s,3H),3.81(s,3H),2.33(s,6H).

[0300] Preparation Example 18

[0301]

[0302] 3-((2,6-dimethylbenzyl)amino)-4-fluorobenzoic acid (A-18)

[0303] Synthesis route:

[0304]

[0305] Step 1: Preparation of 18a

[0306] Using methyl 3-amino-4-fluorobenzoate (1.0 g, 5.91 mmol) and 2,6-dimethylbenzaldehyde (1.19 g, 8.87 mmol) as raw materials, and following a similar procedure to the first step in Preparation Example 11, 18a was obtained, a white solid of 183 mg, with a yield of 11%.

[0307] 1 H NMR(500MHz, CDCl3)δ7.58(d,J=8.5Hz,1H),7.47–7.44(m,1H),7.21–7.18(m,1H),7 .13(s,1H),7.11(s,1H),7.07–7.03(m,1H),4.35(s,2H),3.96(s,3H),2.43(s,6H).

[0308] Step 2: Preparation of A-18

[0309] Using intermediate 18a (180 mg, 0.63 mmol) as a starting material, and following a similar procedure to the second step in Preparation Example 1, A-18 was obtained, a white solid of 135 mg, with a yield of 78%.

[0310] 1H NMR(500MHz,DMSO-d6)δ7.41(dd,J=8.6,2.1Hz,1H),7.25–7.22(m,1H),7.15–7.1 2(m,1H),7.11–7.09(m,1H),7.05(s,1H),7.03(s,1H),4.23(s,2H),2.34(s,6H).

[0311] Preparation Example 19

[0312]

[0313] 3-((2,4,6-trimethylbenzyl)thio)-4-methylbenzoic acid (A-19)

[0314] Synthesis route:

[0315]

[0316] Step 1: Preparation of 19a

[0317] Using methyl 3-iodo-4-methylbenzoate (1.494 g, 5.41 mmol) and (2,4,6-trimethylphenyl)methanethiol (600 mg, 3.61 mmol) as raw materials, and following a similar procedure to the first step in Preparation Example 10, intermediate 19a was obtained, consisting of 363 mg of white solid, with a yield of 32%.

[0318] 1 H NMR (400MHz, DMSO-d6) δ7.92 (d, J = 2.0 Hz, 1H), 7.73 (dd, J = 7.8, 1.8 Hz, 1H), 7.38 (d, J = 8. 0Hz,1H),6.86(s,2H),4.17(s,2H),3.86(s,3H),2.32(s,3H),2.30(s,6H),2.21(s,3H).

[0319] Step 2: Preparation of A-19

[0320] Using intermediate 19a (360 mg, 1.14 mmol) as the starting material, and following a similar procedure to the second step in Preparation Example 10, A-19 was obtained, a white solid of 272 mg, with a yield of 80%.

[0321] 1H NMR (400MHz, DMSO-d6) δ7.92(d,J=2.0Hz,1H),7.70(dd,J=8.0,1.6Hz,1H),7.33(d,J=8.0Hz,1H),6.86(s,2H),4.15(s,2H),2.31(s,9H),2.21(s,3H).

[0322] Preparation Example 20

[0323]

[0324] 3-((2,6-dimethylbenzyl)oxo)-4-bromobenzoic acid (A-20)

[0325] Synthesis route:

[0326]

[0327] Step 1: Preparation of 20a

[0328] Using methyl 4-bromo-3-hydroxybenzoate (1.00 g, 4.33 mmol) and (2,6-dimethylphenyl)methanol (825 mg, 6.06 mmol) as raw materials, and following a similar procedure to the first step in Preparation Example 1, intermediate 20a was obtained, consisting of 1.90 g of a yellow solid, with a yield of 96%.

[0329] 1 H NMR(400MHz, CDCl3)δ7.73(d,J=2.0Hz,1H),7.63–7.61(m,1H),7.55–7.52(m,1H),7 .20–7.16(m,1H),7.09(s,1H),7.08(s,1H),5.16(s,2H),3.94(s,3H),2.43(s,6H).

[0330] Step 2: Preparation of A-20

[0331] Using intermediate 20a (1.90 g, 5.44 mmol) as the starting material, and following a similar procedure to the second step in Preparation Example 1, A-20 was obtained, a white solid of 1.48 g, with a yield of 81%.

[0332] 1 H NMR (400MHz, DMSO-d6) δ7.79(d,J=1.6Hz,1H),7.72(d,J=8.4Hz,1H),7.49(dd,J=8.0 ,2.0Hz,1H),7.20–7.17(m,1H),7.10(s,1H),7.08(s,1H),5.21(s,2H),2.37(s,6H).

[0333] Preparation Example 21

[0334]

[0335] 4-Methyl-3-((2,6-dibromobenzyl)oxo)benzoic acid (A-21)

[0336] Synthesis route:

[0337]

[0338] Step 1: Preparation of 21a

[0339] Using methyl 4-methyl-3-hydroxybenzoate (600 mg, 3.61 mmol) and (2,6-dibromophenyl)methanol (1.344 g, 5.05 mmol) as raw materials, and following a similar procedure to the first step in Preparation Example 1, intermediate 21a was obtained, consisting of 1.477 g of a yellow solid, with a yield of 98%.

[0340] 1 H NMR(400MHz, CDCl3)δ7.68(d,J=1.6Hz,1H),7.62–7.59(m,3H),7.21(dd,J=7 .8,1.0Hz,1H),7.09(t,J=7.8Hz,1H),5.37(s,2H),3.93(s,3H),2.25(s,3H).

[0341] Step 2: Preparation of A-21

[0342] Using intermediate 21a (823 mg, 1.99 mmol) as a starting material, and following a similar procedure to the second step in Preparation Example 1, A-21 was obtained, a white solid of 700 mg, with a yield of 88%.

[0343] 1 H NMR (400MHz, DMSO-d6) δ12.92(s,1H),7.78(s,1H),7.76(s,1H),7.65(d,J=1.6Hz, 1H),7.53(dd,J=7.6,1.6Hz,1H),7.30(t,J=8.0Hz,2H),5.32(s,2H),2.16(s,3H).

[0344] Preparation Example 22

[0345]

[0346] 3-((2,6-dimethylbenzyl)amino)-4-trifluoromethylbenzoic acid (A-22)

[0347] Synthetic route

[0348]

[0349] Step 1: Preparation of 22a

[0350] Using methyl 3-amino-4-trifluoromethylbenzoate (590 mg, 2.69 mmol) and 2,6-dimethylbenzaldehyde (542 mg, 4.04 mmol) as raw materials, and following a similar procedure to the first step in Preparation Example 11, 22a was obtained, a white solid of 79 mg, with a yield of 8%.

[0351] 1 H NMR (400MHz, DMSO-d6) δ7.95–7.89(m,2H),7.76(s,1H),7.29(s,1H),7.17–7.15(m,2H),3.91(s,3H),3.86(s,1H),3.86(s,2H),2.54(s,6H).

[0352] Step 2: Preparation of A-22

[0353] Using intermediate 22a (220 mg, 0.65 mmol) as a starting material, and following a similar procedure to the second step in Preparation Example 1, A-22 was obtained, a white solid of 199 mg, with a yield of 95%.

[0354] 1 H NMR (400MHz, DMSO-d6) δ13.25(s,1H),7.57(d,J=8.0Hz,1H),7.45(s,1H),7.29(d,J=8.0Hz,1H),7.12 (dd,J=8.4,6.0Hz,1H),7.06(s,1H),7.04(s,1H),4.82(brs,1H),4.37(d,J=4.4Hz,2H),2.35(s,6H).

[0355] Preparation Example 23

[0356]

[0357] 3-((2,6-dimethylbenzyl)amino)-4-bromobenzoic acid (A-23)

[0358] Synthetic route

[0359]

[0360] Step 1: Preparation of 23a

[0361] Using methyl 3-amino-4-bromobenzoate (690 mg, 3.0 mmol) and 2,6-dimethylbenzaldehyde (604 mg, 4.5 mmol) as raw materials, and following a similar procedure to the first step in Preparation Example 11, 23a was obtained, a white solid of 170 mg, with a yield of 16%.

[0362] 1 H NMR(400MHz, DMSO-d6)δ7.60(d,J=8.0Hz,1H),7.34(d,J=2.0Hz,1H),7.18–7.10(m,2H),7.07(s, 1H),7.06–7.05(brs,1H),4.68(t,J=4.4Hz,1H),4.32(d,J=4.4Hz,2H),3.84(s,3H),2.36(s,6H).

[0363] Step 2: Preparation of A-23

[0364] Using intermediate 23a (330 mg, 0.95 mmol) as a starting material, and following a similar procedure to the second step in Preparation Example 1, A-22 was obtained, a white solid of 310 mg, with a yield of 97%.

[0365] 1 H NMR (400MHz, DMSO-d6) δ12.99(s,1H),7.57(d,J=8.0Hz,1H),7.36(d,J=2.0Hz,1H),7.18–7.10(m ,2H),7.07(s,1H),7.07–7.04(m,1H),4.56(t,J=4.4Hz,1H),4.31(d,J=4.4Hz,2H),2.35(s,6H).

[0366] Preparation Example 24

[0367]

[0368] 3-((2,6-dimethylbenzyl)amino)-4-cyanobenzoic acid (A-24)

[0369] Synthetic route

[0370]

[0371] Step 1: Preparation of 24a

[0372] methyl 3-amino-4-cyanobenzoate (540 mg, 3.07 mmol) and Molecular sieves were added to a 25 mL round-bottom flask, and anhydrous MeOH (7 mL) was added as solvent. 2,6-Dimethylbenzaldehyde (821 mg, 6.12 mmol) was added, and the reaction was allowed to proceed for 2.5 hours. Then, sodium cyanoborohydride (569 mg, 9.21 mmol) was added, and the reaction was initiated at 60 °C. After 12 hours, TLC showed that most of the starting material had reacted completely. The molecular sieves were removed by filtration, and most of the solvent was removed by rotary evaporation. The residue was then added to 30 mL of water and extracted with DCM (25 mL × 3). The organic phases were combined and washed three times with saturated NaCl aqueous solution. The organic phase was dried over anhydrous sodium sulfate, and the filtrate was concentrated and subjected to silica gel column chromatography (EA / PE = 12 / 88) to give intermediate 24a, a white solid of 425 mg, with a yield of 47%.

[0373] 1 H NMR (400MHz, CDCl3) δ7.44(d,J=8.0Hz,1H),7.32(dd,J=8.0,1.6Hz,1H),7.13(dd,J=8.4,6. 8Hz,1H),7.06(brs,1H),7.04(brs,1H),5.60(s,1H),4.32(s,2H),3.92(s,3H),2.34(s,6H).

[0374] Step 2: Preparation of A-24

[0375] Using intermediate 24a (180 mg, 0.63 mmol) as a starting material, and following a similar procedure to the second step in Preparation Example 1, A-24 was obtained, a white solid of 135 mg, with a yield of 78%.

[0376] 1 H NMR (400MHz, DMSO-d6) δ13.30(s,1H),7.61(d,J=8.0Hz,1H),7.41(d,J=1.6Hz,1H),7.21(dd,J=8.0,1.6Hz,1H),7. 12(dd,J=8.4,6.4Hz,1H),7.07(brs,1H),7.05(brs,1H),6.01(t,J=4.4Hz,1H),4.35(d,J=4.4Hz,2H),2.36(s,6H).

[0377] Example

[0378] Example 1

[0379]

[0380] Synthetic route of N-((4-bromophenyl)sulfonyl)-3-((2,6-dimethylbenzyl)oxy)-4-methylbenzamide (compound 1):

[0381]

[0382] Step 1: Preparation of Compound 1

[0383] Add A-1 (300 mg, 1.1 mmol) to a 25 mL round-bottom flask, add anhydrous DCM as solvent (6 mL), and under ice bath conditions, add DMAP (159 mg, 1.3 mmol) and EDC-HCl (250 mg, 1.3 mmol). After the addition is complete, react at room temperature for 0.5 hours, then add p-bromobenzenesulfonamide (307 mg, 1.3 mmol). After reacting at room temperature for 5 hours, the reaction is confirmed to be complete by TLC. Dilute the reaction solution with DCM (10 mL), wash three times with 2N hydrochloric acid aqueous solution, combine the organic phases, wash three times with saturated brine, dry to anhydrous sodium sulfate, filter, concentrate, and perform silica gel column chromatography (PE / EA = 20 / 80) to give compound 1, 477 mg white solid, yield 89%.

[0384] 1 H NMR (400MHz, DMSO-d6) δ12.55(s,1H),7.95–7.80(m,4H),7.61(s,1H),7.40(d,J=8.0Hz,1H),7.2 3(d,J=7.6Hz,1H),7.15–7.12(m,1H),7.05–7.04(m,2H),5.07(s,2H),2.29(s,6H),2.06(s,3H).

[0385] Example 2

[0386]

[0387] Synthetic route of N-((4-fluorophenyl)sulfonyl)-3-((2,6-dimethylbenzyl)oxy)-4-methylbenzamide (compound 2):

[0388]

[0389] Step 1: Preparation of Compound 2

[0390] Using A-1 (50 mg, 0.19 mmol) as the starting material, the same operating steps as in the third step of Example 1 were followed, except that p-fluorobenzenesulfonamide was used instead of p-bromobenzenesulfonamide, to obtain compound 2, a white solid of 76 mg, with a yield of 97%.

[0391] 1H NMR(400MHz, DMSO-d6)δ7.83(dd,J=8.6,1.8Hz,2H),7.60(s,1H),7.39(d,J=7.6Hz ,1H),7.17–7.09(m,3H),7.03–7.01(m,3H),4.98(s,2H),2.29(s,6H),2.01(s,3H).

[0392] Example 3

[0393]

[0394] Synthetic route of N-((4-chlorophenyl)sulfonyl)-3-((2,6-dimethylbenzyl)oxy)-4-methylbenzamide (compound 3):

[0395]

[0396] Step 1: Preparation of Compound 3

[0397] Using A-1 (50 mg, 0.18 mmol) as the starting material, the same operating steps as in the third step of Example 1 were followed, except that p-chlorobenzenesulfonamide was used instead of p-bromobenzenesulfonamide, to obtain compound 3, a white solid of 47 mg, with a yield of 59%.

[0398] 1 H NMR(500MHz,DMSO-d6)δ7.92(d,J=8.5Hz,2H),7.61–7.58(m,3H),7.41(d,J=7.0Hz ,1H),7.17–7.12(m,2H),7.05–7.04(m,2H),5.05(s,2H),2.30(s,6H),2.05(s,3H).

[0399] Example 4

[0400]

[0401] Synthetic route of N-((4-nitrophenyl)sulfonyl)-3-((2,6-dimethylbenzyl)oxy)-4-methylbenzamide (compound 4):

[0402]

[0403] Step 1: Preparation of Compound 4

[0404] Using A-1 (50 mg, 0.18 mmol) as the starting material, the same operating steps as in the third step of Example 1 were followed, except that p-nitrobenzenesulfonamide was used instead of p-bromobenzenesulfonamide, to obtain compound 4, a white solid of 58 mg, with a yield of 72%.

[0405] 1 H NMR (400MHz, DMSO-d6) δ8.22(d,J=8.8Hz,2H),8.03(d,J=8.8Hz,2H),7.60(s,1H),7. 40(dd,J=7.6,1.6Hz,1H),7.13–7.00(m,4H),4.99(s,2H),2.29(s,6H),2.02(s,3H).

[0406] Example 5

[0407]

[0408] N-(benzenesulfonyl)-3-((2,6-dimethylbenzyl)oxy)-4-methylbenzamide (compound 5)

[0409] Synthesis route:

[0410]

[0411] Step 1: Preparation of Compound 5

[0412] Using A-1 (50 mg, 0.19 mmol) as the starting material, the same operating steps as in the third step of Example 1 were followed, except that benzenesulfonamide was used instead of p-bromobenzenesulfonamide, to obtain compound 5, a white solid of 48 mg, with a yield of 63%.

[0413] 1 H NMR (400MHz, DMSO-d6) δ12.44(s,1H),7.98–7.96(m,2H),7.70–7.66(m,1H),7.62–7.59(m,3H),7.38(dd,J=7.6, 1.6Hz,1H),7.21(d,J=8.0Hz,1H),7.14–7.11(m,1H),7.04–7.03(m,2H),5.06(s,2H),2.28(s,6H),2.05(s,3H).

[0414] Example 6

[0415]

[0416] N-(toluenesulfonyl)-3-((2,6-dimethylbenzyl)oxy)-4-methylbenzamide (compound 6)

[0417] Synthesis route:

[0418]

[0419] Step 1: Preparation of Compound 6

[0420] Using A-1 (50 mg, 0.18 mmol) as the starting material, the same operating steps as in the third step of Example 1 were followed, except that p-methylbenzenesulfonamide was used instead of p-bromobenzenesulfonamide, to obtain compound 6, 40 mg of white solid, with a yield of 53%.

[0421] 1 H NMR (400MHz, DMSO-d6) δ12.36(s,1H),7.83(d,J=8.4Hz,2H),7.59(s,1H),7.38–7.36(m,3H),7.19(d,J =7.6Hz,1H),7.14–7.10(m,1H),7.04–7.02(m,2H),5.05(s,2H),2.35(s,3H),2.28(s,6H),2.04(s,3H).

[0422] Example 7

[0423]

[0424] N-((4-hydroxyphenyl)sulfonyl)-3-((2,6-dimethylbenzyl)oxy)-4-methylbenzamide (Compound 7)

[0425] Synthesis route:

[0426]

[0427] Step 1: Preparation of Compound 7

[0428] Using A-1 (100 mg, 0.37 mmol) as a starting material, the same operating steps as in the third step of Example 1 were followed, except that p-hydroxybenzenesulfonamide was used instead of p-bromobenzenesulfonamide, to obtain compound 7, 30 mg of white solid, with a yield of 20%.

[0429] 1 H NMR(400MHz, CDCl3)δ8.01(d,J=8.8Hz,2H),7.76–7.74(m,2H),7.39(d,J=8.8Hz,2H),7.28(d ,J=8.0Hz,1H),7.19–7.16(m,1H),7.09–7.07(m,2H),5.12(s,2H),2.40(s,6H),2.24(s,3H).

[0430] Example 8

[0431]

[0432] N-(methanesulfonyl)-3-((2,6-dimethylbenzyl)oxy)-4-methylbenzamide (compound 8)

[0433] Synthesis route:

[0434]

[0435] Step 1: Preparation of Compound 8

[0436] Using A-1 (50 mg, 0.18 mmol) as a starting material, the same operating steps as in the third step of Example 1 were followed, except that methanesulfonamide was used instead of p-bromobenzenesulfonamide to obtain compound 8, a white solid of 40 mg, with a yield of 64%.

[0437] 1 H NMR (400MHz, DMSO-d6) δ12.05(s,1H),7.68(s,1H),7.46(d,J=8.0Hz,1H),7.25(d,J=7.6Hz,1 H),7.15–7.11(m,1H),7.05–7.03(m,2H),5.09(s,2H),3.34(s,3H),2.30(s,6H),2.07(s,3H).

[0438] Example 9

[0439]

[0440] N-((trifluoromethyl)sulfonyl)-3-((2,6-dimethylbenzyl)oxy)-4-methylbenzamide (compound 9)

[0441] Synthesis route:

[0442]

[0443] Step 1: Preparation of Compound 9

[0444] Using A-1 (100 mg, 0.37 mmol) as a starting material, the same operating steps as in the third step of Example 1 were followed, except that trifluoromethylsulfonamide was used instead of p-bromobenzenesulfonamide to obtain compound 9, a white solid of 89 mg, with a yield of 60%.

[0445] 1H NMR(400MHz,DMSO-d6)δ7.62(d,J=1.6Hz,1H),7.43(dd,J=7.6,1.6Hz,1H),7 .14–7.08(m,2H),7.04–7.02(m,2H),5.02(s,2H),2.31(s,6H),2.05(s,3H).

[0446] Example 10

[0447]

[0448] N-(ethylsulfonyl)-3-((2,6-dimethylbenzyl)oxy)-4-methylbenzamide (compound 10)

[0449] Synthesis route:

[0450]

[0451] Step 1: Preparation of Compound 10

[0452] Using A-1 (90 mg, 0.33 mmol) as the starting material, the same operating steps as in the third step of Example 1 were followed, except that ethyl sulfonamide was used instead of p-bromobenzene sulfonamide to obtain compound 10, 30 mg of white solid, with a yield of 25%.

[0453] 1 H NMR (400MHz, DMSO-d6) δ11.92(s,1H),7.68(d,J=1.6Hz,1H),7.46(dd,J=7.6,1.6Hz,1H),7.25(d,J=8.0Hz,1H),7.15 –7.11(m,1H),7.05–7.03(m,2H),5.09(s,2H),3.48(q,J=7.4Hz,2H),2.30(s,6H),2.07(s,3H),1.22(t,J=7.4Hz,3H).

[0454] Example 11

[0455]

[0456] N-(propylsulfonyl)-3-((2,6-dimethylbenzyl)oxy)-4-methylbenzamide (Compound 11)

[0457] Synthesis route:

[0458]

[0459] Step 1: Preparation of Compound 11

[0460] Using A-1 (100 mg, 0.37 mmol) as a starting material, the same operating steps as in the third step of Example 1 were followed, except that propylsulfonamide was used instead of p-bromobenzenesulfonamide to obtain compound 11, a white solid of 29 mg, with a yield of 21%.

[0461] 1 H NMR (400MHz, DMSO-d6) δ11.95(s,1H),7.67(s,1H),7.45(d,J=7.6Hz,1H),7.25(d,J=7.6Hz,1H),7.14–7.11(m,1H),7.0 5–7.03(m,2H),5.09(s,2H),3.47(t,J=7.6Hz,2H),2.30(s,6H),2.07(s,3H),1.74–1.65(m,2H),0.96(t,J=7.4Hz,3H).

[0462] Example 12

[0463]

[0464] N-(isopropylsulfonyl)-3-((2,6-dimethylbenzyl)oxy)-4-methylbenzamide (compound 12)

[0465] Synthesis route:

[0466]

[0467] Step 1: Preparation of Compound 12

[0468] Using A-1 (100 mg, 0.37 mmol) as a starting material, the same operating steps as in the third step of Example 1 were followed, except that isopropyl sulfonamide was used instead of p-bromobenzenesulfonamide to obtain compound 12, a white solid of 39 mg, with a yield of 29%.

[0469] 1 H NMR (400MHz, DMSO-d6) δ11.86(s,1H),7.66(s,1H),7.45(dd,J=7.6,1.6Hz,1H),7.25(d,J=8.0Hz,1H),7.15–7. 11(m,1H),7.05–7.03(m,2H),5.09(s,2H),3.85–3.78(m,1H),2.30(s,6H),2.07(s,3H),1.28(d,J=6.8Hz,6H).

[0470] Example 13

[0471]

[0472] N-(tert-butylsulfonyl)-3-((2,6-dimethylbenzyl)oxy)-4-methylbenzamide (compound 13)

[0473] Synthesis route:

[0474]

[0475] Step 1: Preparation of Compound 13

[0476] Using A-1 (175 mg, 0.65 mmol) as the starting material, the same operating steps as in the third step of Example 1 were followed, except that tert-butylsulfonamide was used instead of p-bromobenzenesulfonamide to obtain compound 13, a white solid of 28 mg, with a yield of 11%.

[0477] 1 H NMR (400MHz, DMSO-d6) δ11.42(s,1H),7.61(s,1H),7.41(d,J=7.6Hz,1H),7.23(d,J=7.6Hz,1 H),7.14–7.10(m,1H),7.04–7.03(m,2H),5.08(s,2H),2.30(s,6H),2.06(s,3H),1.37(s,9H).

[0478] Example 14

[0479]

[0480] N-(cyclopropylsulfonyl)-3-((2,6-dimethylbenzyl)oxy)-4-methylbenzamide (compound 14)

[0481] Synthesis route:

[0482]

[0483] Step 1: Preparation of Compound 14

[0484] Using A-1 (300 mg, 1.11 mmol) as the starting material, the same operating steps as in the third step of Example 1 were followed, except that cyclopropylsulfonamide was used instead of p-bromobenzenesulfonamide to obtain compound 14, a white solid of 150 mg, with a yield of 36%.

[0485] 1H NMR (400MHz, DMSO-d6) δ11.99(s,1H),7.67(d,J=1.6Hz,1H),7.46(dd,J=7.6,1.6Hz,1H),7.27–7.25(m,1H),7.1 5–7.12(m,1H),7.06–7.04(m,2H),5.10(s,2H),3.16–3.05(m,1H),2.31(s,6H),2.08(s,3H),1.16–1.03(m,4H).

[0486] Example 15

[0487]

[0488] N-((cyclopropylmethyl)sulfonyl)-3-((2,6-dimethylbenzyl)oxy)-4-methylbenzamide (compound 15)

[0489] Synthesis route:

[0490]

[0491] Step 1: Preparation of Compound 15

[0492] Using A-1 (60 mg, 0.22 mmol) as the starting material, the same operating steps as in the third step of Example 1 were followed, except that cyclopropylmethylsulfonamide was used instead of p-bromobenzenesulfonamide to obtain compound 15, 12 mg of white solid, with a yield of 14%.

[0493] 1 H NMR(400MHz, CDCl3)δ8.46(s,1H),7.53(s,1H),7.31–7.29(m,1H),7.21–7.18(m,1H),7.11–7.09(m,2H),5.10(s ,2H),3.53(d,J=7.2Hz,2H),2.40(s,6H),2.22(s,3H),1.25–1.22(m,1H),0.71–0.70(m,2H),0.43–0.42(m,2H).

[0494] Example 16

[0495]

[0496] N-((1-methylcyclopropyl)sulfonyl)-3-((2,6-dimethylbenzyl)oxy)-4-methylbenzamide (compound 16)

[0497] Synthesis route:

[0498]

[0499] Step 1: Preparation of Compound 16

[0500] Using A-1 (60 mg, 0.22 mmol) as the starting material, the same operating steps as in the third step of Example 1 were followed, except that 1-methylcyclopropylsulfonamide was used instead of p-bromobenzenesulfonamide to obtain compound 16, a white solid of 26 mg, with a yield of 29%.

[0501] 1 H NMR (400MHz, CDCl3) δ8.48(s,1H),7.55(s,1H),7.30(d,J=7.6Hz,1H),7.20–7.15(m,1H),7.08(s,1H ),7.07(s,1H),5.09(s,2H),2.38(s,6H),2.20(s,3H),1.60(s,3H),1.24(s,2H),1.00–0.97(m,2H).

[0502] Example 17

[0503]

[0504] N-(thiophene-2-sulfonyl)-3-((2,6-dimethylbenzyl)oxy)-4-methylbenzamide (compound 17)

[0505] Synthesis route:

[0506]

[0507] Step 1: Preparation of Compound 17

[0508] Using A-1 (50 mg, 0.19 mmol) as the starting material, the same operating steps as in the third step of Example 1 were followed, except that 2-thiophene sulfonamide was used instead of p-bromobenzene sulfonamide to obtain compound 17, a white solid of 71 mg, with a yield of 92%.

[0509] 1 H NMR (400MHz, DMSO-d6) δ8.02(dd,J=4.8,1.6Hz,1H),7.84(dd,J=3.6,1.6Hz,1H),7.62(s,1H),7.41(dd,J=7.6,1.6Hz,1 H),7.24–7.22(m,1H),7.20–7.18(m,1H),7.14–7.11(m,1H),7.05–7.03(m,2H),5.07(s,2H),2.29(s,6H),2.06(s,3H).

[0510] Example 18

[0511]

[0512] N-(pyridine-3-sulfonyl)-3-((2,6-dimethylbenzyl)oxy)-4-methylbenzamide (compound 18)

[0513] Synthesis route:

[0514]

[0515] Step 1: Preparation of Compound 18

[0516] Using A-1 (70 mg, 0.26 mmol) as the starting material, the same operating steps as in the third step of Example 1 were followed, except that pyridine-3-sulfonamide was used instead of p-bromobenzenesulfonamide to obtain compound 18, 80 mg of white solid, with a yield of 75%.

[0517] 1 H NMR (400MHz, DMSO-d6) δ9.11(d,J=2.4Hz,1H),8.86(dd,J=5.0,1.4Hz,1H),8.38–8.35(m,1H),7.70–7.67(m,1H),7.62(d,J=2.0Hz ,1H),7.39(dd,J=8.0,1.6Hz,1H),7.24–7.22(m,1H),7.14–7.10(m,1H),7.04–7.02(m,2H),5.07(s,2H),2.28(s,6H),2.05(s,3H).

[0518] Example 19

[0519]

[0520] N-((4-bromophenyl)sulfonyl)-3-((2,6-dimethylbenzyl)oxy)benzamide (compound 19)

[0521] Synthesis route:

[0522]

[0523] Step 3: Preparation of Compound 19

[0524] Using A-2 (100 mg, 0.39 mmol) as the starting material, and following a similar procedure to step 3 in Example 1, compound 19 was obtained as a white solid, yielding 166 mg in 90% yield.

[0525] 1H NMR (400MHz, DMSO-d6) δ7.71(d,J=8.4Hz,2H),7.54(d,J=8.4Hz,2H),7.51–7.50(m,1H),7.48–7.46(m,1H ),7.20–7.16(m,1H),7.12–7.09(m,1H),7.02–7.00(m,2H),6.98–6.95(m,1H),4.98(s,2H),2.28(s,6H).

[0526] Example 20

[0527]

[0528] N-(cyclopropylsulfonyl)-3-((2,6-dimethylbenzyl)oxy)benzamide (compound 20)

[0529]

[0530] Step 1: Preparation of Compound 20

[0531] Using A-2 as the raw material, and following a similar procedure to the third step in Example 1, compound 20 was obtained, yielding 102 mg of a white solid, with a yield of 36%.

[0532] 1 H NMR(400MHz, CDCl3)δ8.58(s,1H),7.52(s,1H),7.40(s,1H),7.24–7.21(m,1H),7.19–7.16 (m,1H),7.09–7.07(m,2H),5.09(s,2H),2.59–2.53(m,1H),2.38(s,6H),1.20–1.14(m,4H).

[0533] Example 21

[0534]

[0535] N-((4-bromophenyl)sulfonyl)-3-((2,6-dimethylbenzyl)oxy)-4-fluorobenzamide (compound 21)

[0536] Synthesis route:

[0537]

[0538] Step 1: Preparation of Compound 21

[0539] Using A-3 (100 mg, 0.36 mmol) as the starting material, and following a similar procedure to the third step in Example 1, compound 21 was obtained, yielding 132 mg of a white solid with a yield of 74%.

[0540] 1 H NMR (400MHz, DMSO-d6) δ7.76(dd,J=8.4,2.0Hz,1H),7.71(d,J=8.4Hz,2H),7.54(d,J=8.4H z,2H),7.50–7.46(m,1H),7.14–7.05(m,2H),7.03–7.01(m,2H),5.06(s,2H),2.29(s,6H).

[0541] Example 22

[0542]

[0543] N-((4-bromophenyl)sulfonyl)-3-((2,6-dimethylbenzyl)oxy)-4-nitrobenzamide (compound 22)

[0544] Synthesis route:

[0545]

[0546] Step 1: Preparation of Compound 22

[0547] Using A-4 (100 mg, 0.33 mmol) as the starting material, and following a similar procedure to step 3 in Example 1, compound 22 was obtained as a white solid, yielding 87 mg in 51% yield.

[0548] 1 H NMR(400MHz,DMSO-d6)δ7.97(d,J=1.6Hz,1H),7.92–7.88(m,3H),7.85–7.83(m,2H),7.5 5(dd,J=8.4,1.6Hz,1H),7.16–7.12(m,1H),7.04–7.02(m,2H),5.26(s,2H),2.28(s,6H).

[0549] Example 23

[0550]

[0551] N-((4-bromophenyl)sulfonyl)-3-((2,6-dimethylbenzyl)oxy)-4-methoxybenzamide (compound 23)

[0552] Synthesis route:

[0553]

[0554] Step 1: Preparation of Compound 23

[0555] Using A-5 (70 mg, 0.24 mmol) as the starting material, and following a similar procedure to step 3 in Example 1, compound 23 was obtained as a white solid, yielding 86 mg in 71% yield.

[0556] 1 H NMR(500MHz,DMSO-d6)δ12.48(s,1H),7.96(d,J=8.5Hz,2H),7.90(d,J=8.5Hz,2H),7.83 –7.76(m,1H),7.69(d,J=2.0Hz,1H),7.60(dd,J=8.3,2.3Hz,1H),7.21–7.18(m,1H),7.10 -7.08(m,2H),5.09(s,2H),3.81(s,3H),2.34(s,6H).

[0557] Example 24

[0558]

[0559] N-((4-bromophenyl)sulfonyl)-3-((2,6-dimethylbenzyl)oxy)-4-cyanobenzamide (compound 24)

[0560] Synthesis route:

[0561]

[0562] Step 1: Preparation of Compound 24

[0563] Using A-6 (80 mg, 0.28 mmol) as the starting material, and following a similar procedure to step 3 in Example 1, compound 24 was obtained as a white solid, 92 mg, with a yield of 66%.

[0564] 1 H NMR (400MHz, DMSO-d6) δ7.85 (s, 1H), 7.78 (d, J = 8.4Hz, 2H), 7.69–7.67 (m, 1H), 7. 63–7.59(m,3H),7.21–7.17(m,1H),7.10–7.08(m,2H),5.23(s,2H),2.36(s,6H).

[0565] Example 25

[0566]

[0567] N-((4-bromophenyl)sulfonyl)-3-((2,6-dimethylbenzyl)oxy)-4-trifluoromethylbenzamide (compound 25)

[0568] Synthesis route:

[0569]

[0570] Step 1: Preparation of Compound 25

[0571] Using A-7 (64 mg, 0.20 mmol) as the starting material, and following a similar procedure to step 3 in Example 1, compound 25 was obtained as a white solid, 99 mg, with a yield of 90%.

[0572] 1 H NMR(400MHz,DMSO-d6)δ7.90–7.88(m,3H),7.81(d,J=8.4Hz,2H),7.74–7.67(m,1H) ,7.55–7.53(m,1H),7.15–7.12(m,1H),7.05–7.03(m,2H),5.20(s,2H),2.27(s,6H).

[0573] Example 26

[0574]

[0575] N-((4-bromophenyl)sulfonyl)-3-((2,6-dimethylbenzyl)oxy)-2-methylbenzamide (compound 26)

[0576] Synthesis route:

[0577]

[0578] Step 1: Preparation of Compound 26

[0579] Using A-8 (100 mg, 0.37 mmol) as the starting material, and following a similar procedure to step 3 in Example 1, compound 26 was obtained as a white solid, yielding 157 mg in 87% yield.

[0580] 1 H NMR (400MHz, DMSO-d6) δ7.85–7.84(m,3H),8.76–7.69(m,1H),7.30–7.22(m,2H),7.13–7.10( m,1H),7.03–7.02(m,2H),6.91(dd,J=7.6,1.2Hz,1H),5.00(s,2H),2.26(s,6H),1.84(s,3H).

[0581] Example 27

[0582]

[0583] N-((4-bromophenyl)sulfonyl)-5-((2,6-dimethylbenzyl)oxy)-2-methylbenzamide (compound 27)

[0584] Synthesis route:

[0585]

[0586] Step 1: Preparation of Compound 27

[0587] Using A-9 (80 mg, 0.30 mmol) as the starting material, and following a similar procedure to step 3 in Example 1, compound 27 was obtained as a white solid, yielding 154 mg in 94% yield.

[0588] 1 H NMR(400MHz,DMSO-d6)δ7.90–7.83(m,4H),7.76–7.69(m,1H),7.15–7.10(m,2H ),7.07–7.06(m,1H),7.04–7.01(m,2H),5.01(s,2H),2.27(s,6H),2.06(s,3H).

[0589] Example 28

[0590]

[0591] N-(cyclopropylsulfonyl)-3-((2,6-dimethylbenzyl)thio)-4-methylbenzamide (compound 28)

[0592] Synthesis route:

[0593]

[0594] Step 1: Preparation of Compound 28

[0595] Using A-10 (40 mg, 0.14 mmol) as the starting material, and following a similar procedure to step 3 in Example 1, compound 28 was obtained as a white solid, 40 mg, with a yield of 74%.

[0596] 1H NMR(400MHz, CDCl3)δ8.19(s,1H),7.57(s,1H),7.53–7.50(m,1H),7.13–7.09(m,1H),7.03–7.01( m,2H),4.13(s,2H),3.10(s,1H),2.40(s,3H),2.32(s,6H),1.72–1.64(m,2H),1.44–1.40(m,2H).

[0597] Example 29

[0598]

[0599] N-(cyclopropylsulfonyl)-3-((2,6-dimethylbenzyl)amino)-4-methylbenzamide (compound 29)

[0600] Synthesis route:

[0601]

[0602] Step 1: Preparation of Compound 29

[0603] A-11 (60 mg, 0.22 mmol) was added to a 25 mL round-bottom flask, and anhydrous DCM (5 mL) was added as a solvent. Then, HATU (125 mg, 0.33 mmol), Et3N (92 μL, 0.66 mmol), DMAP (3 mg, 0.02 mmol), and cyclopropylsulfonamide (32 mg, 0.27 mmol) were added. The reaction was started at room temperature. After 6 hours, TLC showed that the reaction was almost complete. Water (10 mL) was added, and the mixture was extracted three times with DCM (15 mL). The organic phases were combined and washed three times with saturated NaCl aqueous solution (10 mL). After drying the organic phase with anhydrous sodium sulfate, silica gel column chromatography (EA / PE = 70 / 30) was performed to give compound 29, 10 mg of white solid, yield 14%.

[0604] 1 H NMR(400MHz, CDCl3)δ8.42(s,1H),7.23(s,1H),7.18–7.13(m,2H),7.10(s,1H),7.08–7.05(m,1H) ,4.30(s,2H),3.17–3.11(m,1H),2.37(s,6H),2.09(s,3H),1.46–1.45(m,2H),1.17–1.14(m,2H).

[0605] Example 30

[0606]

[0607] N-(cyclopropylsulfonyl)-4-methyl-3-((2,4,6-trimethylbenzyl)oxy)benzamide (compound 30)

[0608] Synthesis route:

[0609]

[0610] Step 3: Preparation of Compound 30

[0611] Using A-12 (300 mg, 1.06 mmol) as a starting material, and following a similar procedure to step 3 in Example 1, compound 30 was obtained, yielding 155 mg of a white solid in a yield of 38%.

[0612] 1 H NMR (400MHz, DMSO-d6) δ11.98(s,1H),7.66(d,J=2.0Hz,1H),7.45(dd,J=7.8,1.8Hz,1H),7.26(dd,J=7.8,1.0Hz,1H),6. 86(s,2H),5.06(s,2H),3.15–3.08(m,1H),2.27(s,6H),2.20(s,3H),2.07(s,3H),1.14–1.11(m,2H),1.10–1.07(m,2H).

[0613] Example 31

[0614]

[0615] N-(cyclopropylsulfonyl)-3-((4-fluoro-2,6-dimethylbenzyl)oxy)-4-methylbenzamide (compound 31)

[0616] Synthesis route:

[0617]

[0618] Step 3: Preparation of Compound 31

[0619] Using A-13 (200 mg, 0.69 mmol) as a starting material, and following a similar procedure to step 3 in Example 1, compound 31 was obtained, yielding 117 mg of a white solid, with a yield of 43%.

[0620] 1H NMR (400MHz, CDCl3) δ7.56(d,J=2.0Hz,1H),7.34(d,J=7.6Hz,1H),7.20(d,J=7.6Hz,1H),6.78(d,J=9 .6Hz,2H),5.01(s,2H),3.10(s,1H),2.35(s,6H),2.18(s,3H),1.42–1.40(m,2H),1.13–1.11(m,2H).

[0621] Example 32

[0622]

[0623] N-(cyclopropylsulfonyl)-3-((2,6-dimethylbenzyl)thio)-4-methoxybenzamide (compound 32)

[0624] Synthesis route:

[0625]

[0626] Step 1: Preparation of Compound 32

[0627] Using A-14 (100 mg, 0.33 mmol) as the starting material, and following a similar procedure to step 3 in Example 1, compound 32 was obtained as a white solid, yielding 76 mg in 57% yield.

[0628] 1 H NMR (400MHz, DMSO-d6) δ7.93(d,J=2.4Hz,1H),7.87–7.84(m,1H),7.11–7.08(m,1H),7.07(d,J=1.2Hz,1H),7.05(s,1H) ,7.03(d,J=2.8Hz,1H),4.17(s,2H),3.88(s,3H),3.11–3.05(m,1H),2.38(s,6H),1.07–1.04(m,2H),0.99–0.97(m,2H).

[0629] Example 33

[0630]

[0631] N-(cyclopropylsulfonyl)-3-((2,6-dimethylbenzyl)thio)benzamide (compound 33)

[0632] Synthesis route:

[0633]

[0634] Step 1: Preparation of Compound 33

[0635] Using A-15 (150 mg, 0.55 mmol) as the starting material, and following a similar procedure to step 3 in Example 1, compound 33 was obtained as a white solid, yielding 81 mg in 39% yield.

[0636] 1 H NMR (400MHz, DMSO-d6) δ7.96 (s, 1H), 7.79 (d, J = 8.0Hz, 1H), 7.46 (s, 1H), 7.36 (s, 1H),7.06–7.03(m,3H),4.23(s,2H),2.96(s,1H),2.36(s,6H),0.91–0.78(m,4H).

[0637] Example 34

[0638]

[0639] N-(cyclopropylsulfonyl)-3-((4-fluoro-2,6-dimethylbenzyl)amino)-4-methylbenzamide (compound 34)

[0640] Synthesis route:

[0641]

[0642] Step 1: Preparation of Compound 34

[0643] Using A-16 (90 mg, 0.31 mmol) as the starting material, and following a similar procedure to step 3 in Example 1, compound 34 was obtained, yielding 40 mg of a brown solid in a yield of 33%.

[0644] 1 H NMR(500MHz,DMSO-d6)δ11.89(s,1H),7.27(s,1H),7.21–7.19(m,1H),7.07(d,J=7.5Hz,1H),6.93(s,1H), 6.91(s,1H),4.19(d,J=4.5Hz,2H),3.10(s,1H),2.36(s,6H),2.10(s,3H),1.10–1.04(m,2H),1.00(s,2H).

[0645] Example 35

[0646]

[0647] N-(cyclopropylsulfonyl)-3-((2,6-dimethylbenzyl)amino)-4-methoxybenzamide (compound 35)

[0648] Synthesis route:

[0649]

[0650] Step 1: Preparation of Compound 35

[0651] Using A-17 (200 mg, 0.70 mmol) as the starting material, and following a similar procedure to step 3 in Example 1, compound 35 was obtained as a white solid, yielding 166 mg, with a yield of 61%.

[0652] 1 H NMR(500MHz,DMSO-d6)δ11.81(s,1H),7.36(d,J=8.5Hz,1H),7.32(s,1H),7.15–7.10(m,1H),7.08–7.0 6(m,2H),6.93(d,J=8.5Hz,1H),4.24(s,2H),3.82(s,3H),3.14(s,1H),2.33(s,6H),1.14–1.08(m,4H).

[0653] Example 36

[0654]

[0655] N-(cyclopropylsulfonyl)-3-((2,6-dimethylbenzyl)amino)-4-fluorobenzamide (compound 36)

[0656] Synthesis route:

[0657]

[0658] Step 1: Preparation of Compound 36

[0659] Using A-18 (90 mg, 0.33 mmol) as the starting material, and following a similar procedure to step 3 in Example 1, compound 36 was obtained, yielding 43 mg of an off-white solid, with a yield of 33%.

[0660] 1 H NMR(400MHz,DMSO-d6)δ7.50–7.45(m,1H),7.24(s,1H),7.13–7.08(m,2H),7.06(s,1H), 7.04(s,1H),4.24(d,J=4.4Hz,2H),3.07(s,1H),2.35(s,6H),1.04(s,2H),0.96(s,2H).

[0661] Example 37

[0662]

[0663] N-(cyclopropylsulfonyl)-3-((2,6-dimethylbenzyl)oxy)-4-fluorobenzamide (compound 37)

[0664] Synthesis route:

[0665]

[0666] Step 1: Preparation of Compound 36

[0667] Using A-3 (150 mg, 0.55 mmol) as the starting material, and following a similar procedure to step 3 in Example 1, compound 37 was obtained as a white solid, yielding 60 mg in 29% yield.

[0668] 1 H NMR(400MHz, DMSO-d6)δ12.14(s,1H),7.96(dd,J=8.2,2.2Hz,1H),7.64–7.60(m,1H),7.41–7.36(m,1H),7. 22–7.18(m,1H),7.11(s,1H),7.09(s,1H),5.22(s,2H),3.19–3.11(m,1H),2.36(s,6H),1.20–1.08(m,4H).

[0669] Example 38

[0670]

[0671] N-(cyclopropylsulfonyl)-3-((2,4,6-trimethylbenzyl)thio)-4-methylbenzamide (compound 38)

[0672] Synthesis route:

[0673]

[0674] Step 1: Preparation of Compound 38

[0675] Using A-19 (150 mg, 0.50 mmol) as the starting material, and following a similar procedure to step 3 in Example 1, compound 38 was obtained as 100 mg of white solid, with a yield of 50%.

[0676] 1H NMR (400MHz, DMSO-d6) δ12.11(s,1H),7.92(d,J=2.0Hz,1H),7.72–7.68(m,1H),7.36(d,J=8.0Hz ,1H),6.87(s,2H),4.24(s,2H),3.16–3.15(m,1H),2.33(s,9H),2.22(s,3H),1.15–1.12(m,4H).

[0677] Example 39

[0678]

[0679] N-(cyclopropylsulfonyl)-3-((2,6-dimethylbenzyl)oxy)-4-methoxybenzamide (compound 39)

[0680] Synthesis route:

[0681]

[0682] Step 1: Preparation of Compound 39

[0683] Using A-5 (106 mg, 0.37 mmol) as the starting material, and following a similar procedure to step 3 in Example 1, compound 39 was obtained as a white solid (50 mg), with a yield of 35%.

[0684] 1 H NMR (400MHz, DMSO-d6) δ11.92(s,1H),7.75(d,J=2.0Hz,1H),7.64(dd,J=8.6,2.2Hz,1H),7.20–7.16(m,1H),7. 10(d,J=2.0Hz,2H),7.08(s,1H),5.10(s,2H),3.80(s,3H),3.17–3.11(m,1H),2.34(s,6H),1.15–1.08(m,4H).

[0685] Example 40

[0686]

[0687] N-(cyclopropylsulfonyl)-3-((2,6-dimethylbenzyl)oxy)-4-bromobenzamide (compound 40)

[0688] Synthesis route:

[0689]

[0690] Step 1: Preparation of Compound 40

[0691] Using A-20 (150 mg, 0.37 mmol) as the starting material, and following a similar procedure to step 3 in Example 1, compound 40 was obtained as a white solid, yielding 21 mg, with a yield of 11%.

[0692] 1 H NMR(400MHz, DMSO-d6)δ7.83(d,J=2.0Hz,1H),7.61(d,J=8.4Hz,1H),7.50–7.48(m,1H),7.20–7.16(m,1H),7 .10(s,1H),7.08(s,1H),5.18(s,2H),3.06–2.99(m,1H),2.38(s,6H),0.96–0.95(m,2H),0.86–0.85(m,2H).

[0693] Example 41

[0694]

[0695] N-(cyclopropylsulfonyl)-3-((2,6-dibromobenzyl)oxy)-4-methylbenzamide (compound 41)

[0696] Synthesis route:

[0697]

[0698] Step 1: Preparation of Compound 41

[0699] Using A-21 (150 mg, 0.37 mmol) as the starting material, and following a similar procedure to step 3 in Example 1, compound 41 was obtained as a white solid, 21 mg, with a yield of 11%.

[0700] 1 H NMR (400MHz, DMSO-d6) δ7.77(s,1H),7.75(s,1H),7.68–7.66(m,1H),7.51(dd,J=7.6,1.6Hz,1H),7.30(t,J=8.0H z,1H),7.10(d,J=7.6Hz,1H),5.27(s,2H),2.96–2.91(m,1H),2.11(s,3H),0.83–0.80(m,2H),0.70–0.65(m,2H).

[0701] Example 42

[0702]

[0703] N-(cyclopropylsulfonyl)-3-((2,6-dimethylbenzyl)amino)-4-trifluoromethylbenzamide (compound 42)

[0704] Synthetic route

[0705]

[0706] Using A-22 (190 mg, 0.59 mmol) as the starting material, and following a similar procedure to step 3 in Example 1, compound 42 was obtained as a white solid, yielding 48 mg in 19%.

[0707] 1 H NMR (400MHz, DMSO-d6) δ12.25(s,1H),7.60(d,J=8.0Hz,1H),7.47(d,J=1.6Hz,1H),7.28(d,J=8.0Hz,1H),7.14(dd,J=8.0,6.0Hz,1 H),7.08(s,1H),7.06(d,J=1.6HJ,1H),4.75–4.71(m,1H),4.40(d,J=4.0Hz,2H),3.18–3.12(m,1H),2.35(s,6H),1.20–1.12(m,4H).

[0708] Example 43

[0709]

[0710] Synthetic route of N-(cyclopropylsulfonyl)-3-((2,6-dimethylbenzyl)amino)-4-bromobenzamide (compound 43)

[0711]

[0712] Using A-23 (150 mg, 0.45 mmol) as the starting material, and following a similar procedure to step 3 in Example 1, compound 43 was obtained as a white solid, 75 mg, with a yield of 38%.

[0713] 1 H NMR(400MHz, DMSO-d6)δ12.10(s,1H),7.61(d,J=8.0Hz,1H),7.39(d,J=2.0Hz,1H),7.18–7.12(m,2H),7.09(s,1H),7 .07(d,J=2.0Hz,1H),4.53(t,J=4.4Hz,1H),4.35(d,J=4.4Hz,2H),3.18–3.12(m,1H),2.36(s,6H),1.17–1.12(m,4H).

[0714] Example 44

[0715]

[0716] N-(cyclopropylsulfonyl)-3-((2,6-dimethylbenzyl)amino)-4-cyanobenzamide (compound 43)

[0717] Synthetic route

[0718] Using A-23 (275 mg, 0.98 mmol) as the starting material, and following a similar procedure to step 3 in Example 1, compound 44 was obtained as 15 mg of white solid, with a yield of 4%.

[0719]

[0720] 1 H NMR(400MHz, CDCl3)δ8.99(s,1H),7.52(d,J=8.0Hz,1H),7.33(d,J=1.6Hz,1H),7.18(dd,J=8.4,6.4Hz,1H),7.20–7.11(m,2H), 7.09(s,1H),4.48(t,J=4.0Hz,1H),4.37(d,J=4.0Hz,2H),3.14–3.10(m,1H),2.38(s,6H),1.47–1.42(m,2H),1.21–1.15(m,2H).

[0721] Bioactivity test

[0722] Experimental Example 1: In vitro URAT1 activity inhibition test

[0723] Experimental principle: HEK293 cells with stable URAT1 expression were used to inhibit [8- 14 C]Uric acid uptake method to evaluate the in vitro inhibitory effect of target compound on URAT1.

[0724] Experimental methods: The experiment was conducted according to pages 446-447 of the literature (Chinese Journal of Medicinal Chemistry, 2016, 26(6), 437-448).

[0725] Data processing: The transport value of transporter cells in the group receiving only the precipitate substrate (excluding the transport value U0 of the background group, i.e., mock cells, in DPM) was defined as 100% (control, U0). c Using this as a standard, the transport values ​​U of each dosing group after deducting the background and the transport value U of the control group were calculated. cThe percentage (In) is used to calculate the inhibition rate, which characterizes the strength of the compound's inhibitory effect on the transporter. The formula is as follows:

[0726] In = [100 × (U - U0) / (Uc - U0)]%

[0727] IR = 1 - In

[0728] Two replicates were set up for each administered concentration (i.e., n=2), and the Mean ± standard error (SD) was calculated using... Statistical formulas in Excel 2010 are used for calculations. Each value represents the average of an experimental group. The inhibition rate of the test compound at different concentrations is fitted with dose-response curves, and the IC50 of the test compound and the positive control drugs Lesinurad and Benzbromarone on URAT1 inhibition is calculated. 50 value.

[0729] Table 1. Inhibition rate of URAT1 by compounds (10 μM concentration) in the embodiments of the present invention.

[0730] compound IR (%) compound IR (%) Compound 1 95 Compound 2 96 Compound 3 95 Compound 4 97 Compound 5 101 Compound 6 96 Compound 8 100 Compound 9 99 Compound 14 99 Compound 17 99 Compound 18 98 Compound 19 92 Compound 21 86 Compound 22 89 Lesinurad 50 Benzbromarone 97

[0731] Table 2. Inhibition rate of URAT1 by compounds (1 μM concentration) in the embodiments of the present invention

[0732]

[0733]

[0734] Table 3. Half-maximal inhibitory concentrations (IC50) of some compounds in the embodiments of the present invention against URAT1 50 )

[0735] compound <![CDATA[IC 50 (μM)]]> compound <![CDATA[IC 50 (μM)]]> Compound 2 0.56 Compound 3 0.37 Compound 4 0.39 Compound 5 0.26 Compound 6 0.35 Compound 8 0.14 Compound 9 0.57 Compound 10 0.12 Compound 11 0.30 Compound 12 0.14 Compound 13 0.23 Compound 14 0.042 Compound 15 0.40 Compound 16 0.58 Compound 17 0.47 Compound 18 0.51 Compound 20 0.37 Compound 21 0.43 Compound 22 0.74 Compound 28 0.20 Compound 29 0.17 Compound 31 0.42 Compound 33 0.11 Compound 34 0.15 Compound 35 0.088 Compound 39 0.078 Compound 40 0.063 Compound 41 0.17 Benzbromarone 0.47

[0736] As shown in Table 1, the compounds of this invention exhibit good in vitro URAT1 inhibitory activity at a concentration of 10 μM, with significantly better activity than the positive control drug Lesinurad. As shown in Table 2, the compounds of this invention exhibit good in vitro URAT1 inhibitory activity at a concentration of 1 μM, with better activity than the positive control drug Benzbromarone and compounds A-1 and A-11. Table 3 shows that the representative compounds have superior in vitro URAT1 inhibitory activity, with compounds 14, 35, 39, and 40 having the highest IC50 values. 50 The concentrations reached 0.042 μM, 0.088 μM, 0.078 μM and 0.063 μM, respectively, and the activity was significantly better than that of the positive control drug Benzbromarone.

[0737] Experiment Example 2: Cytotoxicity Test

[0738] Assay Method: MTT Assay Principle: Cell viability is determined by the reduction of oxidized 3-(4,5-dimethylthiazo-2-yl)-2,5-diphenyltetrazolium bromide (trade name: thiazolyl) / MTT [3-(4,5-dimethylthiazo-2-yl)-2,5-diphenyltetrazolium bromide] to a poorly soluble blue formazan compound by mitochondrial dehydrogenases (such as succinate dehydrogenase). The formazan compound is dissolved in DMSO and then reacted with the formazan to determine its color. The amount of formazan is positively correlated with the number of viable cells.

[0739] Experimental Methods: 1. Preparation of Cell Suspension. Vero cells cultured to the logarithmic growth phase were digested with 0.25% trypsin for 2-3 minutes. The digestion solution was discarded, and an appropriate amount of culture medium was added. After mixing, 20 μL of the solution was taken and counted under a microscope using a hemocytometer to prepare a cell suspension of appropriate concentration for later use. Simultaneously, a 5 g / L MTT solution was prepared using PBS (phosphate buffered solution), filtered for sterilization, and set aside for later use. 2. Drug Preparation and Cytotoxicity Assay. The test drug was dissolved in DMSO and diluted 50-fold with culture medium to prepare the highest test concentration. Then, serial dilutions were performed at a 1:3 ratio on 96-well plates, with 6 concentrations for each compound, the highest concentration being 64 μg / mL. Each concentration was tested in 6 parallel wells (50 μL / well). The prepared cell suspension was seeded into 96-well plates (50 μL / well) at a cell concentration of 4 × 10⁶ cells / well. 5 Cells / mL. Control wells without drug and blank control wells containing culture medium were also included. After 48 hours of culture, 10 μL of MTT per well was added, and culture continued for another 4 hours. The culture plate was removed, the culture medium in the wells was carefully discarded, and 100 μL of DMSO was added to each well. The mixture was shaken until the formazan particles were completely dissolved, and the optical density (OD) was measured at 570 nm using an enzyme-linked immunosorbent assay (ELISA) reader. 570 3. Data Processing. Cell inhibition percentage (%) = [(cell control OD)] 570 Value - OD of the drug-treated group 570 (value) / (cell control OD) 570 Value - Blank OD 570 [Value] × 100%. The dose-response curve was fitted using Origin 7.0 software to calculate the concentration (IC50) at which the compound inhibited cell activity by 50%. 50 ).

[0740] Table 4. Toxicity of some compounds from the embodiments of the present invention on Vero cells

[0741]

[0742] As shown in Table 4, the compounds of this invention exhibit low cytotoxicity and demonstrate high safety.

[0743] Experiment Example 3: OAT1 Selectivity Test

[0744] Experimental principle: The in vitro inhibitory effect of the target compound on OAT1 was evaluated by inhibiting the uptake of 6-carboxyfluorescein (6-CFL) in HEK293 cells that stably express URAT1.

[0745] Experimental methods: 1. Construction and preservation of MDCK-hOAT1 monoclonal high-expression cells: Cells were cultured in DMEM medium containing 10% fetal bovine serum, 100 u / mL penicillin, and 100 μg / mL streptomycin, and were cultured under 5% CO2, 37℃, and saturated humidity. When the cell confluence was approximately 90%, the cells were digested with 0.25% trypsin-EDTA. 2. Prepare Hank's balanced salt solution (HBSS): Weigh out 0.4g KCl, 0.134g Na2HPO4·12H2O, 0.06g KH2PO4, 0.35g NaHCO3, 0.14g CaCl2, 0.1g MgCl2·6H2O, 8.0g NaCl, 1.0g D-glucose, and 0.05g MgSO4. Slowly add double-distilled water to 1 L, and adjust the pH to 7.4 with 6M hydrochloric acid. 3. Dissolve the test compounds according to their labeled weights in DMSO to prepare a 20mM stock solution. Then, prepare solutions of different concentrations using HBSS (containing 0.1% DMSO) for cell incubation. 4. 6-Carboxyfluorescein (6-CFL, 5μM) was used as the substrate for hOAT1. The concentration was 1.6 × 10⁻⁶. 5 Cells were seeded per well in a 48-well plate. 500 μL of HBSS solution containing the test compound (1 μM) and 6-CFL (5 μM) was added to each well, with two replicates per group. After incubation at 37°C for 10 min, the intracellular 6-CFL fluorescence level was measured, and the inhibition rate was calculated.

[0746] Table 5. Selection of compounds for OAT1 in some embodiments of the present invention

[0747] compound Concentration (μM) OAT1 inhibition% Compound A-1 1 48.4 Compound 14 1 7.3 Benzbromarone 1 37.7

[0748] As shown in Table 5, the inhibitory strength of the above compounds on OAT1 is as follows: compound A-1 > Benzbromarone > compound 14. Compound 14 of this invention has a lower inhibitory effect on OAT1 and has better selectivity for the OATs family.

[0749] Experiment 4: Test of the inhibitory activity of OAT1 and OAT3

[0750] Experimental principle: 6-Carboxyfluorescein (6-CFL) was used as a substrate for hOAT1 and hOAT3 to evaluate the in vitro inhibitory effect of the target compounds on OAT1 and OAT3.

[0751] Experimental methods: 1. Construction and preservation of MDCK-hOAT1 monoclonal and MDCK-hOAT3 polyclonal high-expression cells: Cells were cultured in DMEM medium containing 10% fetal bovine serum, 100 u / mL penicillin, and 100 μg / mL streptomycin, and were cultured at 37°C under saturated humidity and 5% CO2. When the cells reached approximately 90% confluence, they were digested with 0.25% trypsin-EDTA. 2. Prepare Hank's balanced salt solution (HBSS): Weigh out 0.4g KCl, 0.134g Na2HPO4·12H2O, 0.06g KH2PO4, 0.24g NaHCO3, 0.14g CaCl2, 8.0g NaCl, 1.0g D-glucose, 0.098g MgSO4, and 5.96g HEPES. Slowly add double-distilled water to 1L, and adjust the pH to 7.4 by adding 1M NaOH. 3. Dissolve the analyte in DMSO according to the labeled weight to prepare a 5mM stock solution, then dilute with HBSS to 5μM (containing 0.1% DMSO). 4. Select 6-carboxyfluorescein (6-CFL, 2μM) as the classic fluorescent substrate for hOAT1, and 6-CFL (5μM) as the substrate for hOAT3. The uptake time for both is 10min. (4×10⁻⁶) 5 Cells were seeded per well in 24-well plates and allowed to adhere for 24-36 hours before experiments. The culture medium was aspirated, and cells were washed twice with preheated HBSS (37°C) to remove cell surface metabolites and other impurities. 500 μL of HBSS (containing different compounds, 5 μM) was added to each well at 37°C and incubated for 30 min, with two replicates per group. The HBSS was discarded, and 500 μL of HBSS (containing different compounds, 5 μM) and 6-CFL (2 μM / OAT1; 5 μM / OAT3) were added. After incubation at 37°C for 10 min, the incubation medium was discarded, and 1 mL of ice-cold HBSS was immediately added to terminate the uptake reaction. Cells were washed four times. Subsequently, 200 μL of 0.5 M NaOH solution was added to each well to lyse the cells. 100 μL of the supernatant was aspirated into a 96-well plate for fluorescence analysis. The excitation and emission wavelengths of 6-CFL were 485 nm and 528 nm, respectively. The inhibition rate was calculated using the blank solvent group (0.1% DMSO) as the control group.

[0752] Table 6. Investigation of the inhibitory effects of compounds from some embodiments of the present invention on OAT1 and OAT3.

[0753]

[0754] As shown in Table 6, compounds 14, 35 and 39 of the present invention exhibit significantly weaker inhibitory strength against OAT1 than compound A-1 at 5 μM, and compound 35 of the present invention exhibits significantly weaker inhibitory strength against OAT3 than compound A-1, demonstrating good selectivity for OATs.

[0755] Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention. Those skilled in the art can make changes, modifications, substitutions and variations to the above embodiments within the scope of the present invention.

Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof: in, X is selected from O, S, NH; R1 is selected from substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted thiophene, substituted or unsubstituted pyridinyl; R2 is selected from H, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylamino, F, Cl, Br, CN, OH, NO2, NH2, trifluoromethyl, and trifluoromethoxy. R3 is selected from H, C1-C3 alkyl, C1-C3 alkoxy, F, Cl, and Br; The substituent in R1 may be selected from the following groups: hydroxyl, halogen, cyano, amino, nitro, trifluoromethyl, trifluoromethoxy, C 1-3 Alkyl, C 1-3 Alkyl group.

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is represented by general formula (II). in, R1 is selected from substituted or unsubstituted phenyl, substituted or unsubstituted thiophene, or substituted or unsubstituted pyridinyl. R2 is selected from H, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylamino, F, Cl, Br, CN, OH, NO2, NH2, trifluoromethyl, and trifluoromethoxy. The substituent in R1 may be selected from the following groups: hydroxyl, halogen, cyano, amino, nitro, trifluoromethyl, trifluoromethoxy, C 1-3 Alkyl, C 1-3 Alkyl group.

3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is represented by general formula (III). in, X is selected from O, S, NH; R1 is selected from substituted or unsubstituted C1-C6 alkyl groups and substituted or unsubstituted C3-C6 cycloalkyl groups; R2 is selected from H, C1-C3 alkyl, C1-C3 alkoxy, F, Cl, Br, CN, OH, NO2, trifluoromethyl, and trifluoromethoxy. R3 is selected from H, C1-C3 alkyl, C1-C3 alkoxy, F, Cl, and Br; The substituent in R1 may be selected from the following groups: hydroxyl, halogen, cyano, amino, nitro, trifluoromethyl, trifluoromethoxy, C 1-3 Alkyl, C 1-3 Alkyl group.

4. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is represented by general formula (IV). in, R1 is selected from substituted or unsubstituted C1-C6 alkyl groups and substituted or unsubstituted C3-C6 cycloalkyl groups; R2 is selected from H, C1-C3 alkyl, C1-C3 alkoxy, F, Cl, Br, CN, OH, NO2, trifluoromethyl, and trifluoromethoxy. R3 is selected from H, C1-C3 alkyl groups, F, Cl, and Br; The substituent in R1 may be selected from the following groups: hydroxyl, halogen, cyano, amino, nitro, trifluoromethyl, trifluoromethoxy, C 1-3 Alkyl, C 1-3 Alkyl group.

5. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is represented by general formula (V). in, R2 is selected from H, C1-C3 alkyl, C1-C3 alkoxy, F, Cl, Br, CN, OH, NO2, trifluoromethyl, and trifluoromethoxy. R3 is selected from H, C1-C3 alkyl groups, F, Cl, and Br.

6. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is represented by general formula (VI). in, R2 is selected from H, C1-C3 alkyl, C1-C3 alkoxy, F, Cl, Br, CN, OH, NO2, trifluoromethyl, and trifluoromethoxy. R3 is selected from H, C1-C3 alkyl groups, F, Cl, and Br.

7. The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the following:

8. A method for preparing the compound according to any one of claims 1 to 7, comprising the following steps: Compound A reacts with a substituted sulfonamide compound in a suitable solvent under the action of a condensation activator and the catalyst DMAP for 1-24 hours at room temperature to obtain the compound shown in formula (I). The solvent is selected from DMF, dichloromethane, tetrahydrofuran, and acetonitrile; The condensation activator is selected from DCC, DIC, EDC-HCl, HOBt, HATU, HBTU, HCTU, and BOP; X, R1, R2 and R3 are defined as described in any one of claims 1 to 7.

9. Use of the compound of any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof in the preparation of an urate anion transporter 1 (URAT1) inhibitor.

10. A pharmaceutical composition comprising a therapeutically and / or preventively effective amount of the compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutically acceptable excipients.

11. The pharmaceutical composition according to claim 10, further comprising one or more other uric acid-lowering drugs selected from urate anion transporter 1 (URAT1) inhibitors, xanthine oxidase inhibitors, xanthine dehydrogenase or xanthine oxidoreductase inhibitors.

12. The pharmaceutical composition according to claim 11, characterized in that, The xanthine oxidase inhibitor is selected from allopurinol, febuxostat, or topipusta.

13. The use of the compound of any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claims 10, 11 or 12, in the preparation of a medicament for treating hyperuricemia or gout.

Citation Information

Patent Citations

  • Weatherable molding composition having improved surface appearance

    WO2000060007A1

  • Benzoic acid compounds for reducing uric acid

    WO2012033720A1

  • N-substituted pyrimidine sulfonyl-substituted benzamide type small molecular inhibitor for Bcl-2 protein and application thereof

    CN101899008A

  • Compounds for preventing and treating cardiovascular diseases

    CN103319408A